REVIEW article

Front. Oncol., 15 February 2022

Sec. Head and Neck Cancer

Volume 12 - 2022 | https://doi.org/10.3389/fonc.2022.834068

Health-Related Quality of Life, Psychosocial Distress and Unmet Needs in Older Patients With Head and Neck Cancer

  • 1. Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia

  • 2. Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC, Australia

  • 3. Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia

  • 4. Department of Health Services Research, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia

  • 5. Department of Nursing, Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Carlton, VIC, Australia

  • 6. Department of Radiation Oncology, Stephenson Cancer Center, University of Oklahoma, Oklahoma City, OK, United States

Article metrics

View details

40

Citations

7,6k

Views

4,3k

Downloads

Abstract

Head and neck squamous cell carcinoma (HNSCC) is the most common cancer involving the mucosal surfaces of the head and neck and is associated with a number of etiological factors, including cigarette smoking, alcohol and betel nut consumption and exposure to high-risk human papillomavirus. The risk of HNSCC increases with age, peaking in the seventh and eighth decade, but this varies by anatomical and histological subtype. While several advancements have been made in the treatment of head and neck cancer (HNC) in recent decades, undertaking curative treatment still subjects the majority of HNSCC patients to substantial treatment-related toxicity requiring patients to tolerate a gamut of physical, psychological, and emotional demands on their reserves. In conjunction with other patient-related factors, clinicians involved in treating patients with HNSCC may incorporate advancing chronological age into their decision-making process when determining treatment recommendations. While advancing chronological age may be associated with increased concerns regarding physical treatment tolerability, clinicians may also be concerned about heightened vulnerability in various health and wellbeing outcomes. The available literature, however, does not provide evidence of this vulnerability in patients with advancing age, and, in many instances, older patients self-report greater resilience compared to their younger counterparts. While this data is reassuring it is limited by selection bias and heterogeneity in trial and study design and the absence of a consistent definition of the elderly patient with HNSCC. This narrative review article also includes a review of the measures used to assess HRQL, psychosocial outcomes and unmet needs in elderly or older patients with HNSCC.

Introduction

Worldwide, head and neck cancer (HNC) accounts for more than 650,000 cases and 330,000 deaths annually and the majority of these are squamous cell carcinomas (HNSCC) (1). Treatment recommendations depend on many factors, including tumor subsite, stage, and pathologic findings, but typically involves surgery and radiation therapy (with or without systemic therapy) either alone or in combination (2). Proceeding along a curative course of treatment for any HNC exposes survivors to the possibility of permanent impairment, including those required for basic human functioning such as chewing, swallowing, tasting and communicating, and loss in these and other domains may also impose significant psychological and emotional challenges (3). It is therefore incumbent upon the HNC physician to weigh the benefits and risks of all therapeutic options, balancing the chance of cure and cost of suboptimal locoregional treatment against the potential toxicity and negative health and wellbeing impacts of curative-intent treatment. Numerous factors weigh into this decision, including performance status, perceived frailty, social supports, individual preferences for pursuing curative treatment and the individual’s physical and mental reserve, among others. Age, whether chronological or the individuals’ perceived biological age, is but one of a host of factors that clinicians may consider during this process.

There is no readily accepted or reliable threshold for defining an “older” HNC patient to incorporate into clinical decision-making, an observation reflecting the degree of variation in ability, functioning and capacity in older adults. As a consequence, tailored treatment recommendations for older patients have been lacking due to an underrepresentation in clinical trials (4). Defining the optimal treatment strategies for these patients, if they differ at all, should be considered a priority for our specialty given the advancing age of the average HNC patient. In the United States for example, the proportion of HNC patients over the age of 65 years is expected to increase from 54% in 2010 to 66% in 2030 (5). In addition, while much attention has been placed on an epidemic of younger patients presenting with human papillomavirus-associated oropharyngeal cancer (HPV+ OPC) the projected increased number of HPV+ OPC cases in the United States from 2016 to 2029 will be driven almost exclusively by patients over 65 years of age (6, 7). Aggressive treatment is definitely feasible for selected older patients with HNC, but reliance on chronological age in isolation may result in over- or under-treatment, and while functional measures may provide superior discrimination in predicting survival and the tolerability of therapy (814), they are time intensive and require considerable multidisciplinary expertise (15).

But what other factors do we need to consider for the older HNC patient? And where is the patient’s voice within this complex decision-making process? Do preferences for pursuing radical treatment and cure change with age? Do priorities and preferences for different oncological and functional outcomes change with increasing age? Do older patients demonstrate increased vulnerability to adverse health and wellbeing outcomes when aggressive treatment strategies are employed? Do older HNC patients have more unmet needs following completion of treatment? This narrative review will draw on published research incorporating patient-reported outcomes to examine these questions. Where possible, we have narrowed the scope to focus on studies reporting outcomes in HNSCC; however, many of the studies were very broad in their selection criteria (tumour subsite and histology) and treatment received including any treatment modifications that may have been made to improve treatment tolerance in older patients. Out of necessity, where suitable data was otherwise lacking, some mixed studies have been included in this review. It should also be acknowledged that specific details about patients’ baseline functional performance were lacking, and the presented studies largely included older patients considered fit for a radical course of treatment, introducing a degree of selection bias. Hence, these results cannot be extrapolated to poorly performing older patients.

Defining “Elderly” Head and Neck Cancer Patients

There is no strict chronological boundary for defining “elderly” patients with cancer. The United Nations and World Health Organization have defined elderly patients as those above 60 (16), while in many developed countries, the designation is tied to retirement, which varies between jurisdictions from 55 to 70 years of age (17). Further refinement of old, including young old (65–74), older old (75–84) and oldest old (≥85) have been proposed and adopted by the National Institute on Aging (18). The European Organization for Research and Treatment of Cancer (EORTC) recommended a cut-off of 70 years of age for their elderly HRQL module, the EORTC QLQ-ELD14 (19). Specifically in HNC, 70 years of age would be considered the most common clinically utilized threshold for decision-making available (4) based on the reported reduction in efficacy of concurrent chemotherapy observed in patients above this threshold (20). However, older patients have typically been underrepresented in HNC and HNSCC clinical trials (4), and caution should be observed in drawing too firm a conclusion given the significant improvement yielded in younger cohorts and the catastrophic complications of treatment failure. While the additional benefit of chemotherapy to locoregional treatment in the elderly remains an unresolved issue, it remains a fertile area of research, one where future studies, in particular, secondary analyses from phase II and III studies, could address questions of efficacy while also providing prospective and high quality data on patient-reported toxicity, HRQL and distress. Such data may provide clinically useful information to aid shared-decision making in older patients with HNSCC.

While there is conjecture and variation surrounding an exact age-related definition of elderly, it is somewhat arbitrary; instead, clarifying core variables such as biological age, medical co-morbidity and frailty lie at the heart of what the clinician is trying to ascertain – whether the patient has sufficient reserve to tolerate the physiological insults of radical treatment. While there has been some tantalizing preliminary work focusing on methods to determine an individuals’ epigenetic clock in HNC patients, it is currently difficult, if not impossible, to measure biological age reliably. This will be discussed in more detail in a subsequent section (21, 22). We acknowledge the limitations of chronological age as a predictor for treatment tolerance, particularly when used in isolation; however, it is a parameter that is commonly used both in clinical and research settings and the purpose of this review was to address variations in health and wellbeing outcomes based on chronological age, rather than other variables, which may provide useful additional data.

Treatment and Outcome Preferences in Older Patients With HNC and HNSCC

Do older patients with HNC prioritize oncologic outcomes, such as cure, survival and functional outcomes like preserving swallow and communicating, differently than younger patients with HNC? The Chicago Priority Scale is one of the most frequently used instruments in the HNC cancer literature to characterize treatment outcome priorities (23, 24). Patients (or controls) are asked to rank their disease and functional outcome goals in order from first to last for 12 different outcomes; these are listed in Table 1. In the first of these studies, which included newly diagnosed HNC patients (n=131) from nine institutions, older patients less frequently prioritized oncological outcomes, such as cure and survival (“living as long as possible) in the top three items. The median age in this study was 59 years (range 29-87 years). In those patients aged <55 years, 55-64 years and >65 years, the frequency of ranking the cure item in the highest three priorities was 98%, 96% and 84%, respectively. While this difference was statistically significant (p<0.05), it is clear that the vast majority of older patients place a high value on being cured of their cancer. Interestingly, the older patients did less frequently prioritize length of life or survival, with the “living as long as possible” outcome showing a more notable drop off in the top three ranked items across the same three age groups (73%, 48% and 43%, respectively, p=0.01).

Table 1

Oncological Outcome
“being cured of my cancer”
“living as long as possible”
Treatment-related outcome
“keeping my natural voice”
“being able to chew normally”
“being able to swallow all foods and liquids”
“having no pain”
“keeping my appearance unchanged”
“returning to my regular activities as soon as possible”
“having a normal amount of energy for me”
“keeping my normal sense of taste and smell”
“being understood easily”
“having a comfortably moist mouth”

Chicago priorities scale.

List et al. subsequently reported results for a larger sample of recently diagnosed, but untreated HNC patients (n=247) in parallel to a control sample (n=131) of non-cancer patients with no personal experience of HNC in close friends or relatives. Similar findings were observed, with most of the “older” group of patients in this series (older was defined by the median split at >58 years) placing the cure outcome in the top three outcomes (≤58: 93% vs >58: 87%). However, older patients also prioritized the “keeping appearances unchanged” item in the top three items more frequently than younger patients (13% vs 5%). Similar observations for both cure, length of life and appearances were observed in the control group.

The Chicago Priority Scale was also used to assess preferences in a more contemporary cohort of patients from John Hopkins, which importantly included many patients with HPV+ OPC (88/150, 59%) (25). Investigators conducted a one-time interview of patients with a mix of HNSCC tumor sites and treatments (surgery ± adjuvant therapy 70%, primary CRT/RT 30%), and the time since treatment completion also varied (median 7 months, IQR 1.5-23.5 months). The median age in this study was lower than in both prior studies (median 54, IQR 54-67, range 26-90). Cure was considered the highest priority at all ages with no differences reported with increasing decade of life. Like both studies by List and colleagues, survival (“living as long as possible”) was less important with increasing age, a finding unchanged after adjustment for HPV status, disease stage and HRQL scores. In the full cohort, the survival outcome was ranked the second most important outcome after cure (median rank 2.5, IQR 2-9), in those aged 75 or over the median rank of the survival outcome was only 6 (IQR 2-11). Nonetheless, there was wider variability in the ranking of the survival item in older patients. In this study, treatment regret using the Ottawa Decision Regret Scale also did not vary by age. In a smaller series of 37 HPV+ OPC patients also from John Hopkins which included patients aged <60 years (23/37,62%), 60-69 years (7/37, 19%) and ≥70 years (7/37, 19%), Windon et al. noted few changes in treatment priorities from baseline (median 1 month after diagnosis, IQR 1-2 months) to post-treatment (median 8 months after treatment, IQR 7-10 months) with the exception that the chewing normally item was increasingly prioritized with older age in the post-treatment setting compared to its initial ranking.

Patient preferences have been appraised in other settings, for instance, where survival may be traded for reduced toxicity or organ preservation. In a Canadian study, Brotherston et al. reported that 51 previously-treated (≥3 months earlier) oropharyngeal cancer patients were willing to accept very little reduction in survival for a reduction in toxicity (which, in this case, was omitting chemotherapy), and when analyzed by age (median age 58 years; 60-69 years: 19/51, 37%, ≥70 years 4/51, 8%) there were no differences in cure sacrifice thresholds (26). In patients treated for advanced laryngeal cancers, at least one study has shown that age was not significantly associated with variations in the willingness to trade laryngeal preservation for survival (27).

In the studies reviewed, cure remains a high priority for HNC patients irrespective of age. Treatment outcome priorities and preferences studies provide some useful broad concepts to guide clinicians but are not a surrogate for eliciting preferences from patients at an individual level, which must remain first and foremost in any shared decision-making model.

Health-Related Quality of Life

A large number of studies have examined age-related variations in health-related quality of life (HRQL) outcomes; however, these reports vary in design (longitudinal or cross-sectional) and how age has been included as a variable (categorical or continuous) in the analysis. Relevant studies have been tabulated for ease of reference, including longitudinal (Table 2) and cross-sectional studies (Table 3) that have modeled age as a categorical variable, single-arm studies enrolling only elderly patients (Table 4) and those that have modeled age as a continuous variable (Table 5). Yet another strategy in the literature has been to compare the outcomes of elderly patients to age-matched population controls, allowing the authors to account for changes expected with normal aging.

Table 2

AuthorYearnLocationHandling of ageaH&N subsiteTreatmentInstrumentsStudy designGlobal QoL findingsOther HRQL findings
Global QoL favoring older
Berg et al. (60)2021311Sweden<70 vs ≥70 years;
<80 vs ≥80 years
OCC, 31%
OPC, 35%
LC, 17%
Other, 27%
Sx, 15%
Sx + aRT/CRT, 22%
RT, 19%
RT/CRT, 44%
QLQ-C30
QLQ-H&N35
QLQ-ELD14
Prospective: pretreatment, 3m, 6m, 12m post RxGlobal QoL favored elderly at 3 months only:
≥70 (<70 vs ≥70: 52 vs 61, p=0.006); and
≥80 (<80 vs ≥80: 54 vs 67, p=0.024)
Most HRQL scores similar or better in older patients, with exception of PF; older patients less appetite loss and FD; oldest (≥80 years) worse fatigue, RF and feeling ill at 12months
Citak and Tulek (61)201354Turkey<60 vs ≥60 yearsLC, 67%
OCC, 19%
Pharynx, 15%
All received RT
Sx, 69%
Any RT, 63%
Any CRT, 38%
QLQ-C30
QLQ-H&N35
Prospective: pretreatment, end of RT, 1m and 3m post RT; factors analysed at end of RT;Global QoL better in older (53 vs 41, p=0.021)Only senses problems (25 v 47, p=0.011) and weight loss (59 v 87, p=0.017) SS and worse in younger patients; remainder not SS
Global QoL favoring younger
Aoki et al. (62)2019172Japan<75 vs ≥75 yearsOCC, 100%Sx, 100%
aRT/CRT, 10%
FACT-H&NProspective: pretreatment, 1, 3 and 6 months post RxGlobal score similar at start but younger better at 6 months posttreatment in favour of younger (106 vs 97)SWB and HNC additional concerns worse at 6m in elderly group; non-elderly group showed improvement at 6m in PWB, EWB and FWB, while the elderly group did not
Age associated with other HRQL domain scores other than global QoL
De Graeff et al. (63)2000107The Netherlands<60 vs ≥60 yearsOCC, 46%
OPC, 6%
HPC, 3%
LC, 43%
Other, 2%
Sx alone, 27%
RT, 45%
Sx + aRT, 28%
QLQ-C30
QLQ-H&N35
Prospective: pretreatment, 6, 12, 24, 36m post RxGlobal QoL not SS (absolute values not reported)PF worse in older SS (absolute difference not reported); remaining items/scales not SS
De Graeff et al. (64)2000153The Netherlands<60 vs ≥60 years4 groups based on site and treatmentLC, RT, 44%
OCC/OPC, Sx, 22%
OCC/OPC, Sx + aRT, 26%
HPC/LC, Sx + aRT - 7%
QLQ-C30
QLQ-H&N35
Prospective: pretreatment, 6m and 12m post Rx;Global QoL not SSOlder patients’ worse fatigue, PF, social eating and speech; remainder NS
Derks et al. (65)2004183The Netherlands45-60 vs ≥75 yearsOCC, 48%
Pharynx, 37%
LC, 15%
Sx, 23%
Sx ± adj RT, 48%
RT, 16%
CRT, 11%
QLQ-C30
QLQ-H&N35
Prospective: pretreatment, and 3m, 6m and 12m post RxGlobal QoL similar at all time points;PF better* in younger at baseline (78 v 69), 3m (65 v 57), 6m (72 vs 62), not SS at 12m (70 vs 62);
Pain worse in younger (37 vs 17) only at 6m post;
remainder NS or trivial differences
Dziegielewski et al. (66)201381USA<55 vs ≥55 yearsOPCAll TORS
aRT/CRT, 87%
HNCIProspective: pretreatment, and 3w, 3m, 6m and 12m post SxGlobal QoL NS (81 v 70, p=0.11)No difference in other functional outcomes; younger patients reported lower attitude (satisfaction) on speech (71 vs 88) and aesthetic (73 v 91)
Funk et al. (67)2012337USA≤58 vs ≥59 yearsMixed subsite; Mixed RxSF-36
HNCI
Prospective, multiple time points; baseline at pretreatment; current study reports at 5 years;Age not SS (72.0 vs 76.0, NS)Older age SS better aesthetics, social disruption, mental health and depressive symptoms but worse physical health
Hammerlid et al. (68) and Bjordal et al. (69)2001357Norway Sweden<65 vs ≥65
years
OCC, 38%
LC, 24%
OPC, 10%
HPC, 8%
Other, 20%
QLQ-C30
QLQ-H&N35
Prospective: pretreatment to 12mGlobal QoL not SS at baseline (68 v 70) or change from baseline to 12m (3 v 1)At baseline:
Older tended to report worse scores, but only significant for PF, constipation, dyspnoea and coughing; Older patients better EF
12m post:
Older higher sexuality and sticky saliva problems;
Older better RF, EF, but reported
Change from baseline to 12m
Older better RF and smaller increase in dry mouth scale; Older larger changes in senses (16 v 10), sexuality (17 v 4) and nutritional supplements (10 v 5)
Hammerlid et al. (68)2001232Sweden<65 vs ≥65 yearsOCC, 32%
Pharynx, 28%
LC, 29%
Other, 22%
Sx alone, 5%
Sx + aRT, 25%
Sx + aCRT, 9%
CRT, 31%
RT, 30%
QLQ-C30
QLQ-H&N35
Prospective: pretreatment, 6 times in year 1, then year 3Global QoL not SS (76 vs 79)Older reported worse mucous production, more problems with sexuality and feeling ill; but less financial difficulties and better EF and less insomnia; SS in PF favoring younger (89 vs 81)
Reeve et al. (70)2016587USA<50 vs 50-64 vs 65-74 vs ≥75 yearsOCC, 53%
LC, 38%
Pharynx, 10%
Sx, 57%
RT, 77%
Chemo, 41%
FACT-H&NProspective: (baseline = mean 3m post diagnosis, + 2 other time pointsTotal FACT-H&N not reportedOlder patients reported better PWB, EWB, FWB and fewer symptoms than younger patients but not SWB
Rettig et al. (71)20161653USA<67 vs 68-72 vs 73-77 vs >78 yearsLC, 38%
OCC, 23%
OPC, 18%
Lip 12%
HPC, 4% Other, 5%
RT, 59%Combined SF-36 PCS/MCS score or Veterans RANDProspective, baseline within 5 years of diagnosis and follow up with 10y posttreatmentComposite PCS/MCS estimated differences:
UVA (p<0.001);
Ref group <67
68-72: 3.9 (1.5,6.3)
73-77: 2.6 (-.1,5.1)
>78: -2.0 (-4.6,0.5)
MVA: (p=0.01)
Ref group <67
68-72: 1.9 (-0.1,3.9)
73-77: 1.0 (-1.0,3.0)
>78: -1.3(-3.4,0.9)
Van Der Schroeff et al. (72)200659The Netherlands45-60 vs ≥70 yearsOCC,51%
Pharynx, 30%
LC, 19%
Mixed site; mixed RxQLQ-C30
QLQ-H&N35
Prospective: pretreatment, 12m, 3-6yGlobal QoL NS at all time pointsOlder group worse PF at 12m (81 v 66) and 3-6y (81 vs 67);
older group worse symptoms on QLQ-H&N35, including social eating at 12m, swallowing at 12m and 3-6y and speech 12m and 3-6y
Age not associated with any HRQL domain scores
Bozec et al. (73)200865France<70 vs ≥70 yearsMixed subsite (61/65 SCC)
OCC, 87%
HPC, 11%
PNS, 2%
All Sx with microvascular reconstruction;
Preop RT 20%
aRT 65%
QLQ-C30
QLQ-H&N35
Prospective: pretreatment, 6m, 12m; analysis of factors limited to 6m postGlobal QoL at 6m similar (63 vs 67; p=0.74)No differences in functioning scales or other domains
Bozec et al. (74)201860France<70 vs ≥70 yearsPrimary or recurrent OPC SCCAll Sx and RFFF
aRT, 41%
aCRT, 35%
QLQ-C30
QLQ-H&N35 (included other PROMs)
Prospective: pretreatment and ≥12m post Rx; analysis of factors after treatmentGlobal QoL not SS (absolute values not reported; p=0.43)No differences in functioning scales or other domains
Bozec et al. (75)2019200France<65 v >65 yearsOCC, 41%
OPC, 20%
HPC, 10%
LC, 28%
All Sx;
aRT, 21%
aCRT, 24%
QLQ-C30
QLQ-H&N35
Prospective: pretreatment and 6m post Rx; analysis of factors after treatmentGlobal QoL not SS (absolute values not reported; p=0.89)No differences in functioning scales or other domains
Derks et al. (76)2003129The Netherlands45-60 vs ≥75 yearsOCC, 64%
OPC/HPC, 27%
LC, 9%
All Sx
aRT, 69%
QLQ-C30
QLQ-H&N35
Prospective: pretreatment and then 2-3 months, adj RT completed at beginning of RTGlobal QoL not SSNo other domains different either at baseline or in changes from baseline
Durmus et al. (77)201422USA<55 vs >55 yearsCUPAll TORS + aRT/CRTHNCIProspective: pretreatment, 3w, 3m, 6m, 12m post SxAge NS for global QoLAge NS for all items/scales
Segna et al. (78)201830Italy<70 vs ≥70 yearsOCCAll reconstructive microsurgery
aRT, 43%
aCRT 17%
SF-36/SF-12Prospective: pretreatment and 12m post SxNo differences in any domains or composite scores
Yin et al. (79)2020294China<60 vs ≥60 yearsHPV OP SCCSx alone, 35%
Sx + aRT, 20%
RT, 45%
QLQ-C30
QLQ-H&N35
Prospective: pretreatment and 3-6m post Rx; factors analyzed post RxAge not a factor on MVA for global QoLAge not a factor for other reported outcomes
Yoshimura et al. (80)200956Japan≤65 vs >65 yearsOCCOCC treated with LDR-BTQLQ-C30
QLQ-H&N35
Prospective: pretreatment, 3m, 6m and 12m post LDR-BTAge NS for global QoLAge NS for any outcome

Prospective studies reporting health-reported quality of life in elderly patientsa.

aRT/CRT, adjuvant radiotherapy/chemoradiotherapy; CRT, chemoradiotherapy; EF, emotional functioning; EWB, emotional wellbeing FACT-HN, Functional Assessment of Cancer Therapy-Head &Neck; FWB, functional wellbeing; H&N, head and neck; HNC, head neck cancer; HNCI, Head Neck Cancer Inventory; HRQL, health-related quality of life; HPC, hypopharyngeal cancer; LC, laryngeal cancer; MCS, Mental Component Summary; MVA, multivariate/variable analysis; NS, not statistically significant; OC, oral cavity; OPC, oropharyngeal cancer; PCS, Physical Component Summary; PF, physical functioning; PWB, physical wellbeing; QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30; QLQ-ELD14, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Elderly Cancer Patients module; QLQ-H&N35, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Head and Neck module; QOL, quality of life; RF, Role functioning; RT, radiotherapy; Rx, treatment; SF-12, Short Form-12 Health Survey; SF-36, Short Form-36 health survey; SS, statistically significant; SWB, social wellbeing; Sx, surgery; UVA, univariate/variable analysis.

a

Definition of elderly and age groups based on categorizations used in the analysis of Global QoL scores.

Table 3

AuthorYearnLocationHandling of ageH&N subsiteTreatmentInstrumentStudy designGlobal QoL findingsOther findings
Alicikus et al. (81)2008110Turkey≤60 vs >60 yearsLC, 58%
NPC, 18%
OC/OPC, 14%
Other, 6%
All received RT/CRT
RT, 42%
CRT, 13%
aRT, 43%
aCRT, 2%
QLQ-C30
QLQ-H&N35
Cross-sectional (median 29m, range 4-155m)Global QoL not SS (69 v 70)PF, RF, SF, CF not different (EF not reported); younger patients reported more problems with teeth (44 vs 18) and opening mouth (30 v 15);
Baxi et al. (82)2018185USA<65 vs ≥65 yearsAll HPV+ OPCAll received RT/CRT definitive, 86%
Adjuvant, 14%
EQ-5D, QLQ-H&N35Cross-sectional (>12 months from RT)Global QoL (EQ-5D VAS) similar (86 vs 81; p=0.20)Older patients worse mobility (EQ-5D), remainder of EQ-5D similar; worse social eating (ED 11.1, p<0.0001) and coughing (ED 11.7, p=0.009)
Bonzanini et al. (83)202090Brazil<62 vs ≥62 yearsOCC/OPC, 60%
LC, 34%
HPC, 6%
All received RT
Sx + aRT, 19%
Sx + aCRT, 40%
RT, 7%
CRT, 34%
UW-QoLCross-sectionalMean scores 60 vs 74; age SS on MVAYounger patients reported worse pain (64 v 81), appearance (70 vs 81), swallowing (56 v 75), chewing (55 v 70), shoulder problems (56 v 84), saliva (43 v 59)
Bozec et al. (84)202064France<80 vs >80 years (inc ≥70 years)All OC/OPCAll free flap reconstruction
Sx alone, 22%
aRT, 61%
aCRT, 17%
QLQ-C30
QLQ-H&N35
QLQ-ELD14
Cross-sectional (>12 months after Sx)Global QoL not SS (value NR)Mobility score on QLQ-ELD14 favouring younger 16.7 vs 22.0, p=0.004); remainder not SS
Dwivedi et al. (85)201255United Kingdom<60 vs ≥60 yearsOCC and OPCAll Primary Sx
Sx alone, 11%
Sx + aRT, 49%
Sx + aCRT, 40%
UW-QoLCross-sectionalMean composite score of 12 domains used - younger worse (70 vs 80, p=0.01);
Infante-Cossio et al. (86)2009128Spain<65 vs >65 yearsOCC, 55%
OPC, 45%
NRQLQ-C30
QLQ-H&N35
Collected at time of diagnosisAge not SS for global QoL (median 83.3 vs 83.3, p=NS)PF, CF, fatigue, pain worse in older patients (all p<0.05, based on median scores, all scores <10 except for fatigue)
Laraway (87)2012638United Kingdom<55 vs 55-64 vs 65-74 vs ≥75 yearsAll OCCSx, 99%
Sx + aRT/CRT, 32%
CRT/RT, 1%
UW-QoLCross-sectional; “closest to 1 year after surgery”Patients ≥65 reported better overall QoL (proportion reporting good or better, p<0.001)Many domains favored the older age groups in both the physical and socioemotional domains
Morimata et al. (88)2013100Japan65 vs >65 yearsMaxillectomy, 50% Mandibulectomy, 50%Maxillectomy, 54% aRT
Mandibulectomy, 32% aRT
UW-QoL (v4.0)Cross-sectionalAge not SS for global QoL in either maxillectomy (p=0.80) or mandibulectomy population (p=0.54)Maxillectomy:
younger patients more anxious (p=0.01)
Mandibulectomy:
younger patients better swallowing (p=0.01), saliva (p=0.04) and mood (p=0.03)
Pierre et al. (89)201480France<70 vs >70 yearsOCC, 46%
OPC, 54%
All Surgical patients with microvascular reconstruction
aRT, 69%
naRT, 11%
QLQ-C30
QLQ-H&N35
Cross-sectionalAge NS for global QoLAge NS for all items/scales
Pourel et al. (90)2002113France≤62 vs >62 yearsAll OPCSx + RT, 23%
BT + RT, 43%
RT, 33%
QLQ-C30
QLQ-H&N35
Cross-sectional (≥2y post RT)Global QoL not SS (66 vs 64, p=0.70)Other functional scales, fatigue did not differ; pain worse in younger (32 vs 21, p=0.03)
Silvieri et al. (91)2011289Portugal40-60 vs ≥65 yearsYounger:
LC, 31%
OC, 16%
OPC, 11%
Older:
LC, 30%
OC, 13%
OPC, 3%
Younger:
Sx, 71%
RT, 8%
CT, 10%
CRT, 11%
Older:
Sx, 79%
RT, 14%
CT, 2%
CRT, 5%
QLQ-C30
QLQ-H&N35
Cross-sectional (3-9m post Rx)Global QoL similar across all groups when analyzed by genderSome small-sized differences reported (i.e. younger males less constipation, worse financial difficulties; older females worse PF (medium-sized), remainder differences small-sized
Few significant differences in QLQ-H&N35 in young vs older males, except for higher sexuality problems in older males (26 vs 39); for females, only speech problems were clinically significant and borderline SS in younger (35 v 18)
Verma et al. (92)201958USA<65 vs ≥65 yearsHNSCC, further details NRDefinitive RT/CRT, 50%
Sx + aRT/naRT, 50%
CT, 72%
QLQ-C30, Dental health, shoulder functionCross-sectionalGlobal QoL NSOlder patients’ better RF (95 vs 76), EF (89 vs 79) and lower pain (4 vs 29), insomnia (8 vs 36) an financial problems (8 vs 38)
Wells et al. (93)2015289United Kingdom<45 vs 45-54 vs 55-64 vs 65-74 vs ≥75 yearsOCC, 34%
OPC, 20%
LC, 33%
Other, 13%
Sx alone, 26%
Sx + aRT, 11%
Sx + CT, 1%
Sx + aCRT, 23%
RT, 17%
CRT, 18%
QLACSCross-sectional (≥3m but <5y post Rx)Generic QoL:
younger not SS (83.8 vs 82.9 vs 79.8 vs 70.0 vs 73.3, p=0.118); higher score = worse)
Cancer-specific QoL:
younger worse (43.8 vs 46.8 vs 40.5 vs 34.1 vs 31.5, p<0.001) (higher score = worse)
Williamson et al. (94)201141USA<70 vs ≥ 70 yearsAll LCSx + aRT/CRT, 27%
RT, 63%
CRT, 10%
UW-QoLCross-sectionalAge NS for overall QoL (even when ≥75 was compared)Age NS for other items/scales
Woodard et al. (95)200733USA≤65 vs >65 yearsAll LC/HPCLaryngectomy, 100%
± adj and previous RT/CRT
HNCICross-sectional (mean 37m)Older SS better global QoL 75 vs 54)Older SS better in all 4 domains (speech, eating, social disruption, aesthetic)

Cross-sectional studies reporting health-reported quality of life in elderly HNSCC cohorts. .

aRT/CRT, adjuvant radiotherapy/chemoradiotherapy; CF, cognitive functioning CRT, chemoradiotherapy; ED, estimated difference; EF, emotional functioning; EQ-5D, EuroQoL 5-Dimension; H&N, head and neck; HNCI, Head Neck Cancer Inventory; HPC, hypopharyngeal cancer; LC, laryngeal cancer; MVA, multi- variate/variable analysis; NR, not recorded; OC, oral cavity; OPC, oropharyngeal cancer; QLACS, Quality of Life of Adult Cancer Survivors; QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30; QLQ-ELD14, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Elderly Cancer Patients module; QLQ-H&N35, European Organization for Research and Treatment of Cancer Quality of Life-Head and Neck module; QoL, Quality of life; PF, physical functioning; RF, Role functioning; RT, radiotherapy; SF, Social functioning; SS, statistically significant; Sx, surgery; UW-QoL, University of Washington Quality of Life instrument.

Table 4

AuthorYearnLocationAges includedParticipantsInstrumentStudy designFindings
Dimovska et al. (28)201634United Kingdom≥80 yearsSx with microsurgical reconstructionUW-QoL (v4)Cross-sectionalOverall score represented mean of the physical and socioemotional domains, 78.7; physical function mean score, 76.52; socioemotional mean score, 80.9
Fang et al. (29)201459China≥70 yearsComparison of surgical patients with and without free flap reconstructionUW-QoL (v4.0)Cross-sectional (≥12m post Rx)Mean composite QoL similar (77.5 vs 72.1, p=0.231); SS differences favoring free flap group in chewing (69.0 vs 57.0)
Ferri et al. (10)201939Italy>75 yearsSx with microsurgical reconstructionSF-36Cross-sectionalAverage score of all scales was 68.3; MCS, 44.6; PCS, 46.5
Highest scale: Physical, 76.92; Lowest scale: energy/fatigue, 60.25
Compared to general population: PCS was higher in this group (46.53 vs 37.85)
Ruhle et al. (30)202150Germany≥65 yearsDefinitive and adjuvant RT/CRTQLQ-C30
QLQ-H&N35
Cross-sectional (≥12m post Rx)Median global QoL (66.7) comparable to German age- and gender matched cohort (65.3); Global QoL similar between definitive and adjuvant CRT (median 75 vs 66.7, p=0.219); HPV+ had superior global QoL to HPV-

Studies reporting health-related quality of life outcomes enrolling only elderly patients with HNSCC.

HPV, human papillomavirus, MCS, Medical Component Summary; PCS, Physical Component Summary; QoL, quality of life; QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30; QLQ-H&N35, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Head and Neck module; Rx, treatment; SF-36, Short Fom-36 Health Survey; Sx, surgery; UW-QoL, University of Washington Quality of Life instrument.

Table 5

AuthorYearnLocationAgeH&N SubsiteTreatmentInstrumentStudy DesignGlobal QoL findingsOther findings
Prospective
Borggreven et al. (31)200780The NetherlandsMean 58 years (23-74 years)OCC, 47%
OPC, 53%
All composite resections + microvascular reconstruction
aRT/CRT, 93%
QLQ-C30
QLQ-H&N35
Baseline and 6m and 12m post RxOlder age associated with worse global QoL at 6m (p=0.041), but not at 12m (raw scores not provided)NR
Hu et al. (32)2020105ChinaMean 60.3 years
(NR)
LC, 69%
HPC, 7%
NPC, 6%
OCC, 6%
OPC, 3%
Other, 9.5%
All SxQLQ-C30Prospective; baseline, 3-9 days post and 1m post SxOlder age SS worse global QoL at 1m post onlyOlder age associated with worse PF at baseline (B=-0.089) and 1m (B=-0.047)
Ronis et al. (33)2008316USAMean 58.6 years
(28-86 years)
OC, 22%
Pharynx, 54%
LC, 25%
Any Sx, 51%
Any RT, 86%
Any CT 65%
SF-36; HNQoLProspective; baseline and 12m;Age negatively and SS with PCS (SF-36); improved emotion domain HNQoL; NS for all other domains
Singer et al. (34)2014133GermanyMean 58 years (38-88 years)All LCAll laryngectomy
aRT, 13%
No aRT, 61%
Unknown, 26%
QLQ-C30
QLQ-H&N35
Prospective, baseline, discharge, end of rehab, 12m post; factors analyze as difference at 12m vs baseline; age as continuous variable;Age NS for global QoL;Age not associated with any outcome
Cross-sectional
Allison et al. (35)1998188CanadaMean 64.6 years (range 34-91 years)OCC, 40%
Pharyngeal, 30%
LC, 30%
Sx alone, 26%
RT alone 33%
Sx + aRT, 42%
QLQ-C30Cross-sectional (mean time since treatment 22m, range 1-168m)Global QoL not correlated on UVA model (r= -0.03, p=0.65); but older age significantly worse on MVA model using clinical and sociodemographic variables (parameter estimate -0.04, SE 0.01, p=0.0003)
McDowell et al. (36)TBD136AustraliaMean 61 years (42-87 years)All HPV OPCRT alone, 12%
CRT, 88%
QLQ-C30Cross-sectional (≥12m post Rx); mean 3.0y from treatment;Age NS for global QoL (p=0.579)Other domains not analyzed by age; age did not differ in a low and high functioning subgroup based on a cluster analysis of QLQ-C30 functioning domains
Mehanna and Morton (37)200643New ZealandMean 64 years (NR)OCC, 14%
LC, 52%
Pharyngeal, 17%
Other, 17%
Mixed site
Mixed Rx
Auckland QoL QuestionnaireCross-sectionalAge NS for Global QoL (aggregated life satisfaction score)
Raemakers et al. (38)2011396The NetherlandsMean 63.2 years
(20-99 years)
OCC, 13%
Pharyngeal, 29%
LC, 32%
Other 25%
All patients RT
Sx, 35%
CT, 14%
EQ-5DCross-sectional (median 20m post Rx)Age not a factor on MVA model for either utility or VAS score
Rogers et al. (39)200965USAMean 60years (NR)OCC, 25%
Pharyngeal, 40%
LC, 20%
Other, 15%
All Sx
RT, 82%
CT, 40%
FACT-H&NCross-sectional (>6m post Rx)Age not SS factor for FACT-G or FACT-H&NOlder patients better EF

Studies reporting age-related differences in health-related quality age in HNSCC (age analyzed as a continuous variable).

H&N, head and neck; QOL, quality of life; LC, laryngeal cancer; HPC, hypopharyngeal cancer; NPC, nasopharyngeal cancer; OC, oral cavity; OPC, oropharyngeal cancer; Sx, surgery; QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30; ART, adjuvant radiotherapy; CRT, chemoradiotherapy; QLQ-H&N35, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Head and Neck module; Rx, treatment; NR, not recorder; RT, radiotherapy; CT, chemotherapy; SF-36, Short Form-36 Health Survey; HNQOL, Head Neck Quality of Life instrument; PCS, Physical Component Summary; UVA, univariate/variable analysis; NS, not statistically significant; MVA, multivariate/variable analysis; EQ-5D, EuroQoL 5-Dimension instrument; VAS, visual analog scale; FACT-HN, Functional Assessment of Cancer Therapy-Head and Neck module.

For this narrative report, we have focused and drawn attention to studies which have measured HRQL outcomes longitudinally with pretreatment assessments as their baseline, as of the numerous available studies, they are best placed to assess and report treatment-related differences across the age continuum. We have also drawn specific attention to those studies demonstrating significant age-based differences in HRQL, whether these differences have favored either the older or younger patients. However, it should be noted that these studies have also varied in study design from small underpowered studies to studies with very large numbers of patients while also using a variety of approaches to model age, including different age-based thresholds, hampering direct comparison. There is also variation in the instruments used and their assessment times. While the European Organization for Research and Treatment of Cancer (EORTC) modules, discussed below, have been the most frequently used measures in these studies, other instruments have been used, and cross-study comparisons are difficult given differences in their content, response options and the time frame with which individual instruments ask patients to consider how they have performed for a given item (i.e., “during the last week” or “during the past 4 weeks”). These are important differences to consider when comparing studies.

Health-Related Quality of Life Instruments

A variety of instruments are available to assess HRQL in HNC populations (Table 6). These include: (1) generic measures, which may also be used in non-cancer populations, such as the Short Form Health Surveys (SF-36, SF-12) (41, 42) or the EuroQoL modules (40); (2) generic cancer measures, such as the EORTC quality of life core questionnaire (QLQ-C30) (43) and the FACT-General (FACT-G) instrument (45); (3) head and neck cancer-specific instruments including the University of Washington Quality of Life Questionnaire (UW-QOL) (53), the EORTC Quality of Life Questionnaire Head and Neck Module (EORTC-QLQ-H&N35/43) (47, 48), and the Functional Assessment of Cancer Therapy Head and Neck (FACT-H&N), which includes the FACT-G and an additional HNC concerns module (49). Many of these HRQL tools are recommended and available for use in elderly HNC patients, but development and validation studies have not always included sufficient numbers of elderly patients (54). Many authors have recognized this problem, and while steps have been taken to develop psychometrically sound tools to measure HRQL in elderly cancer patients, such as the QLQ-ELD14/15 module developed by the EORTC (19, 55), often these tools do not address cancer-specific challenges faced by older HNC patients. For instance, HNC patients were not represented in the development phase of the QLQ-ELD14 (55). Thus, in selecting instruments for any given study investigating HRQL in elderly HNC patients, choices will largely depend on the clinical context and no single instrument is likely to assess all issues relevant to elderly HNC patients.

Table 6

InstrumentGlobal QoL measureNo. of items contributing to global scoreDomainsValidation cohortTarget population
Generic
EuroQoL 5-Dimension (EQ-5D) (40)Yes1 (VAS)Mobility, self-care, usual activities, pain/discomfort, anxiety/depressionGeneral population≥12 years
SF-12 Health Survey (SF-12) (41)NoPhysical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, mental healthaGeneral population≥18 years
SF-36 Health Survey (SF-36) (42)NoPhysical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, mental healthaGeneral population≥18 years
Cancer-Specific
EORTC QLQ-C30 (43)Yes2Physical, role, emotional, cognitive, social functioning; fatigue, pain, nausea and vomiting, dyspnea, insomnia, appetite loss, constipation, diarrhoea; financial impactVersion 1: 36-91 years (mean 63 years) (43);
Version 3: 22-91 years (mean 63 years) (44)
≥30 years
FACT-G (45)Yes27Physical, social, emotional, functional wellbeingItem generation 27-86 years≥18 years
Head and Neck Cancer-Specific
Auckland Quality of Life Questionnaire (AQLQ) (46)Yes1Social, family and physical functioningRange not reported (mean 62 years)Not specified
EORTC QLQ-H&N35/43 (47, 48)NoH&N35: pain, swallowing, senses, speech, social eating, social contact, sexuality; and teeth, mouth opening, dry mouth, sticky saliva, coughing, felt ill, pain killers, nutritional supplements, feeding tube, weight loss, weight gain
H&N43: pain in the mouth, swallowing, teeth, dry mouth and sticky saliva, senses, speech, body image, social eating, sexuality, problems with shoulder, skin problems, fear of progression; and opening mouth, coughing, social contact, swelling in the neck, weight loss, wound healing, neurological problems
H&N35 phase 3: 32-89 years18-88 years
FACT-HN (49)Yes37FACT-G domains plus HNC-specific issues17-82 years (mean 58 years)≥17 years
Head and Neck Quality of Life Instrument (HNQOL) (50)Yes20Communication, discomfort, eating, and emotionAge range not reported
(77.4% > 50 years)
≥18 years
Head and Neck Cancer Inventory (HNCI) (51)Yes1Speech, eating, social disruption and aesthetics<55-≥75 years (mean 61.3 years); 15% ≥75 yearsNot specified
UW-QoL v4 (52)Yes1Physical and social-emotional function; 12 single item symptom scores: pain, appearance, activity recreation, swallowing, chewing, speech, shoulder, taste, saliva, mood, anxietyVersion 1: 23-83 years (mean 55 years); 5/75 (6.5%) ≥70 years≥18 years

Health-related quality of life instruments often used in HNC studies.

EORTC QLQ-C30, European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30; FACT-G, Functional Assessment of Cancer Therapy-General; FACT-HN, Functional Assessment of Cancer Therapy-Head & Neck module; HRQL, health-related quality of life; UW-QoL,- University of Washington Quality of Life Questionnaire; VAS, visual analogue scale.

a

Domain scores are used to calculate a Physical Component Summary score and a Mental Component Summary score.

Global Quality of Life

Despite their limitations (56, 57), global measures of HRQL (referred to hereafter as global QoL) provide a straightforward means of assessing the overall impact of cancer and its treatment (5659). Most prospective studies including measures of global QoL have found no significant differences between younger and older HNC patients (Table 2) (63, 64, 6680) or have found significantly better self-reported global QoL in older patients (6062). Findings from cross-sectional studies are similar (Table 3).

Berg et al. recently investigated longitudinal HRQL trajectories in 311 Swedish HNC patients. The sample included patients with various tumor sites, stages of disease and treatment; 37% had surgery and 85% received RT or CRT, either as definitive (63%) or adjuvant (22%) treatment (60). HRQL measures (EORTC QLQ-C30, QLQ-H&N35, QLQ-ELD14) were completed at diagnosis, then at three, six and 12 months from the commencement of treatment. The authors undertook two sets of analyses to compare younger and older patients. The first compared younger and older patients (<70 vs ≥ 70 years), the second compared younger and oldest patients (<80 vs ≥80 years). Despite similar global QoL at baseline, older patients reported better global QoL (<70 vs ≥70 years: 52 vs 61, p=0.006) three months after treatment, a difference of borderline clinical significance (96, 97); the oldest group (<80 vs ≥80 years: 54 vs 67, p=0.024) also fared better on global QoL at three months. Differences at three months were no longer evident at subsequent follow-ups. Citak et al. reported a prospective study of 54 Turkish patients, all of whom underwent radiotherapy (adjuvant treatment in 69%) (61). HRQL was captured with the EORTC QLQ-C30 and QLQ-H&N35 at baseline, at the end of RT, and one and three months after treatment. Global QoL was better in the older cohort (<60 vs ≥60 years: 53 vs 41, p=0.021) at the end of RT. While clinically relevant (96, 97), score differences at baseline were not described, so these results should be interpreted with caution.

Conversely, in a study reporting HRQL in elderly Japanese patients with oral cancer, Aoki et al. reported lower global QoL in older patients six months after treatment (62). In this study, 172 patients (≥75 years, n=43) completed the FACT-H&N at baseline, at treatment completion and one, three- and six-months post-treatment. While differences were small at the earlier time points, older patients reported worse global QoL scores at six months post-treatment (graphical interpretation, 106 vs 97, p=0.009), which falls into the range of a clinically meaningful difference (98). Interestingly, younger patients showed continued improvement from completion of treatment, whereas older patients plateaued at 1-month post-treatment.

Other Health-Related Quality of Life Outcomes

While considerable attention has been given to global QoL outcomes, other HRQL outcomes are highly relevant to older HNC patients and worth exploring in more detail. As with global QoL, most prospective studies fail to demonstrate consistent age-related differences in other self-reported HRQL outcomes (7380), with some differences attributable to normal aging, irrespective of whether the patient has cancer.

In a prospective study of HNC patients from Sweden and Norway, Hammerlid et al. reported worse baseline (at the time of diagnosis) scores for older patients (≥75 years) on multiple scales/items of the QLQ-C30 and H&N35; however, these differences were only clinically relevant (≥10) for physical functioning, constipation, dyspnea and coughing. Older patients, however, reported better emotional functioning (99). At the 12-month follow-up, older patients (≥65 years) reported better role (difference = 11) and emotional functioning (difference = 10) but more significant problems with sexuality (difference = 18) and sticky saliva (difference = 15) than younger patients (69). Further, older patients reported less significant changes from baseline in role functioning and dryness of mouth. Nonetheless, changes from baseline in the senses (16 vs 10), sexuality (17 vs 4) and nutritional supplements (10 vs 5) were more severe.

In the previously mentioned Swedish study by Berg et al., the authors reported similar or better scores in the older cohorts with the exception of physical functioning, which was uniformly better in younger patients across the study. One exception was at the 3-month assessment. Here, differences in physical functioning were neither clinically nor statistically significant. This is largely explained by more significant declines in younger patients between baseline and 3 months. With further follow-up and recovery, however, the younger group regained its initial advantage. Older patients also reported less appetite loss and financial difficulties at various time points in this study (60). Notably, the oldest patients (≥80 years) reported worse fatigue, role functioning, and feeling ill at 12 months compared to those under 80 years. The Turkish study, which reported better global QoL at the end of RT, also found that older patients fared better with regards to senses problems and reported less weight loss, but scores were similar in other domains (61). Aoki et al., on the other hand, reported significantly worse social wellbeing and more HNC concerns in older patients (>75 years) at 6 months, as assessed by the FACT-H&N. Again, this appeared to be explained by younger patients showing better and ongoing recovery with further follow-up compared to the older patients.

Longitudinal HRQL outcomes for 785 HNC patients were collected in a North Carolina study using the FACT-H&N, with questionnaires administered to newly diagnosed HNC patients who were then assessed again at two subsequent follow-ups (median 22- and 42-months post-treatment, respectively) (70). Like most prospective studies reviewed, this series contained patients with various HNC subsites and disease stages, and they were treated with any combination of surgery (57%) and/or radiation (77%), with many also receiving concurrent chemotherapy (41%). A linear mixed model incorporating time since follow-up was used on each of the wellbeing domains, but not the total score. Age was divided into four categories, <50 years (19%), 50-64 years (49%), 65-74 years (25%) and ≥75 years (7%). Older patients generally fared better, with superior scores across the physical, emotional and functional wellbeing domains and the HNC additional concerns subscale. No significant differences were observed on the social wellbeing domain.

Physical functioning has also been reported as worse in older patients in other series, sometimes as an isolated finding among all available items/scales/domains (63), or in conjunction with limited other differences (76). While many of these studies suggest that older patients are not more adversely affected, some studies, such as that by Van Der Schroeff et al. have shown worse outcomes (72). In this longitudinal study, 118 older (≥70 years) and 148 younger (45-60 years) patients were followed for three to six years. The QoL component of the study was limited to those who completed all HRQL questionnaires (n=24 and n=33 patients, respectively). Again, the study sample was quite heterogenous in terms of tumor site, disease stage and treatment received. In the QoL cohort, about half the patients had oral cavity cancers. Patients were enrolled at diagnosis and there were no differences in the baseline EORTC QLQ-C30 and H&N35 scores. A more significant decline in physical functioning was seen in the older patients by 12 months post-treatment and this difference persisted at follow-up (i.e. three to six years post-treatment). The older patients also tended to report worse HNC symptoms, including statistically and clinically significant worse social eating (43 vs 23), swallowing (32 v 19) and speech (30 vs 19) at 12 months. Score differences on the swallowing and speech measures remained statistically significantly and clinically worse in the older patients with longer follow-up.

Laryngectomy Patients

Singer et al. conducted a prospective study of patients undergoing laryngectomy in eight German centers (34). HRQL data was collected at prior to undergoing a laryngectomy, just before hospital discharge, during inpatient rehabilitation, and 12 months later (EORTC QLQ-C30 and QLQ-H&N35). In this study, 101/175 (58%) patients were aged <60 years, 51/174 (29%) were aged 60-69 years, and 22/174 (13%) were ≥70 years. A multivariable regression analysis was undertaken to explore variations in HRQL changes from baseline to 12 months. While several outcomes, such as physical, role and social functioning, and some of the symptom items from both the QLQ-C30 and H&N35 were significantly worse one year after laryngectomy, age (analyzed as a continuous variable) was not a significant ‘predictor of scale/item scores’. On the other hand, Woodard et al. conducted a cross-sectional study in laryngectomy survivors using the Head and Neck Cancer Inventory (HNCI). Analysis of HNCI scores was limited to 33/58 survivors at median follow-up of 37 months post laryngectomy. The study included patients who had received primary surgical treatment and those who had received salvage surgery, however, the final patient contributions to the HRQL data was not reported. Younger patients (<65 years, 15/33) fared far worse across all the functional and attitude domains, as well as the global QoL score (54 vs 75). Those patients needing a laryngectomy as a component of their cancer treatment represent a distinct survivorship cohort amongst HNC patients, one resulting in many HRQL challenges, including loss of communication, body image changes and, potentially, loss of functional employment. While all patients will no doubt struggle with the physical and psychological impacts of a laryngectomy, younger patients in the prime of their adult lives may be especially vulnerable to the consequence of this life changing event.

Comparison to Age- and Gender-Matched Populations

Several studies have contrasted the outcomes of elderly patients to age- and gender-matched cohorts to differentiate HRQL changes attributable to treatment vulnerability and those that may be expected as a consequence of aging alone. Ferri et al. reported the outcomes of patients aged >75 years who had undergone HNC surgery with microsurgical reconstruction. This multi-site cross-sectional study used the SF-36 to assess HRQL two years after surgery. Of the eligible patients, 76/115 had died, leaving 39/115 enrollees with an average age of 81 years at the time of surgery. Most patients had also received adjuvant treatment (26/39, 67%). While the Mental Component Summary scores were similar to an age-matched Italian cohort, the average Physical Component Summary scores for the treated cohort indicated better physical health (46.5 vs 37.9) compared to the age-matched population. In a series of 50 older patients (>65 at time of treatment) who were at least one year from curative-intent radiotherapy (definitive or adjuvant), Ruhle et al. contrasted cross-sectional HRQL outcomes to an age-matched German sample (30). Using the EORTC QLQ-C30, patients reported very similar global QoL to the matched group. However, social functioning (85 vs 71), appetite loss (8 vs 19) and constipation (7 vs 20) were worse in the treated group; conversely, pain scores were lower (22 vs 33).

In a larger study also from Germany, 817 patients were enrolled to a cross-sectional study which compared HRQL, emotional distress and fatigue in HNC patients to a gender- and aged-matched population (<65 years, n=476; and ≥65 years, n=341) (100). The study sample included all HNC subtypes and a mix of primary and adjuvant treatment. Younger treated patients were more adversely affected (larger negative impacts) compared to their age- and gender-matched peers across all measured outcomes. Even so, older patients (≥65 years) did report worse HRQL compared to their matched peers. Global QoL (EORTC QLQ-C30) was worse for both the older males (65 vs 54) and females (63 vs 54). Older patients also reported worse fatigue (males 45 vs 24, females 48 vs 25) compared to the non-cancer patients.

Psychosocial Distress

The term “distress”, in the context of cancer, was chosen by the NCCN because it is felt to be less stigmatizing than descriptors like “psychiatric” and “psychosocial” concerns. It is defined by the NCCN as “a multifactorial, unpleasant, emotional experience of a psychological (cognitive, behavioral, emotional), social, and/or spiritual nature that may interfere with the ability to cope effectively with cancer, its physical symptoms, and its treatment (101)”. It encompasses both normal feelings such as vulnerability, sadness, and fears, as well as problems that can significantly impact a patient’s life such as depression, anxiety, panic, social isolation, and personal crisis (101).

This report has focused on multiple types of distress, including the more commonly appreciated forms anxiety, depression and suicidality, but also other measures including fear of cancer recurrence, post-traumatic stress disorder, coping strategies and body image distress. This section will also discuss what is known about pain, fatigue, and sleep in older patients with HNC. Where possible, this review has focused on longitudinal, prospective studies, but this was not always possible for some of the less frequently studied outcomes, and where cross-sectional studies have provided novel or additional information, they have been included. The variation in instrument selection in these reports is considerable, and as for the HRQL section, cross-comparison is limited by significant variations in their content and application.

Instruments Measuring Psychosocial Distress in HNC

Tools commonly used to measure distress in HNC research are listed in Table 7. While most HRQL measures include mental health and/or wellbeing scales, this section will focus on tools specifically designed to assess anxiety, depression and/or distress. These include: (1) generic measures which may also be used in a non-cancer population, such as the Geriatric Depression Scale (GDS), Hospital Anxiety and Depression Scale (HADS), Beck Depression Inventory (BDI), and Patient Health Questionnaire 9 (PHQ-9); (2) generic cancer measures, such as the Distress Thermometer (DT), Mini-Mental Adjustment to Cancer (Mini-MAC), and Distress Inventory for Cancer (DIC2); and (3) head and neck cancer specific instruments, such as the Patient Concerns Inventory (PCI). Additionally, there are tools for assessing other factors that directly impact patient distress levels, such as coping style, fear of cancer recurrence, fatigue and sleep, social support, pain, and body image. These will be discussed in their respective sections.

Table 7

InstrumentDomains coveredValidation cohort age rangeRecommended Age use
Generic
Geriatric Depression Scale (GDS) (102)DepressionGeneral elderly population≥65 years
Hospital Anxiety and Depression Scale (HADS) (103)Anxiety and depressionGeneral medical population≥18 years
Patient Reported Outcomes Measurement Information System (PROMIS) (104)Anxiety and DepressionPatients with chronic conditions≥18 years
Beck Depression Inventory (BDI) (105)DepressionPsychiatric & normal populations, ≥13 years13-80 years
Center for Epidemiological Studies Depression (CES-D) Scale (106)DepressionGeneral population, ≥18 years≥18 years
State-Trait Anxiety Inventory (STAI) (107)Anxiety about an event and as a personal traitGeneral population≥18 years
Hamilton Depression Rating Scale (HAM-D) (108)DepressionHospital inpatients ≥18 years≥18 years
Mini-International Neuropsychiatric Interview (MINI) (109)Major psychiatric disordersGeneral population≥18 years
Quick Inventory of Depressive Symptomatology-Self Report (QIDS-SR) (110)DepressionGeneral population≥18 years
Coping Orientation to Problems Experienced (COPE) questionnaire (111)Assesses ways in which people respond to stressHas been validated in various stressed populations≥15 years
Patient Health Questionnaire 9 (PHQ-9) (112)DepressionGeneral population≥12 years
Brief Illness Perception Questionnaire (B-IPQ) (113)Cognitive illness representations: consequences, timeline, personal control, treatment control, concern, emotions, and comprehensibilityChronically ill patients, age not listed≥8 years
Acute Stress Disorder Inventory (ASDI) (114)Screening instrument to identify acute traumaTrauma populations≥18 years
Cancer-Specific
Distress Thermometer (DT) (115)Psychological distressAdult cancer patients≥18 years
Mini - Mental Adjustment to Cancer (Mini-MAC) (116)Fighting spirit, positive redefinition, helplessness – hopelessness, anxious preoccupationCancer patients aged 18-75 years≥18 years
Distress Inventory for Cancer (DIC2) (117)Psychological distressCancer patients aged 18-88 years≥18 years
head and Neck Cancer-specific
Patient Concerns Inventory (PCI) (118)Physical and functional wellbeing, treatment-related issues, social wellbeing, psychological wellbeingHNC patients, ≥18 years≥18 years

Common Instruments used to capture distress in HNC studies.

Anxiety and Depression

Patients receiving HNC therapy self-report high levels of psychological distress, depression, and anxiety (119). Despite this awareness, psychological issues often remain unidentified or unassessed, albeit with significant effects on quality of life, functional status, and survival (8). Social isolation and lack of support have been linked to higher cancer mortality rates and poorer treatment tolerance (120). This is especially concerning in an older patient population because many elderly patients live alone (121). Literature on interventions to improve QOL and mood in patients with HNSCC have been summarized elsewhere (122).

Many studies have explored the relationship between age, and anxiety and depression in HNC patients. Due to the sheer volume of published studies, this paper will focus on results from prospective longitudinal studies (Table 8); results from cross-sectional studies are largely compatible. The overwhelming majority of prospective studies indicate that older HNC patients experience either similar rates of anxiety and depression (72, 74, 141156), or less of one or both (123138), than do their younger counterparts. Results from very few studies indicate worse distress among older HNC patients (139, 140).

Table 8

AuthorYearnLocationAgeH&N subsiteTreatmentInstrumentsStudy designFindings
Measures favoring older
Cash et al. (123)201855USAMedian 58.5 years; range 24-82 yearsMixedMixedPHQ-9Prospective: baselineIncreases in cognitive/affective symptoms correlated with younger age (age as continuous variable) (p=.012)
Chen et al. (124)200940USAMedian 55 years (38-90 years)Non-metastatic HNSCCHad to include RT (definitive or adjuvant)BDI-II
HADS-Depression
Prospective: baseline, last day of RT, & first follow-up visitAge <55y significantly associated with post-RT depression on both scales; levels rose during RT & remained elevated at first follow-up visit (p=<.05)
D’Souza et al. (125)201396CanadaMedian ~59 yearsStage III-IV HNSCCMixedHADSProspectiveDepression significantly associated with age (p=0.04), with younger pts having higher levels of depression
Ghazali et al. (126)2017261United KingdomMedian 63 yearsMixed
Post-treatment NED
MixedDT
UWQOL
Prospective: at least 6w post-treatmentHigher distress rates for those <55y (p=0.04)
Hammerlid et al. (127)1999357Norway SwedenMean 63 years (18-88 years)MixedMixedHADSProspective multicenter: baseline and 1, 2, 3, 6, & 12mPatients under 65y scored higher on mental distress scale at diagnosis and 1y than patients >65
Horney et al. (128)2010103United KingdomMean 63 yearsMixedMixedHADS
LOT-R
Brief COPE
SF-12 v2
Prospective: baselineYounger age significantly associated with Pre-treatment anxiety & negative coping styles (p=.0001)
Howren et al. (129)2010306USAMean 60 yearsMixedMixedBDI
HNCI
Prospective: baseline, 3m, & 12mYounger age predicted worse social disruption at 3m follow-up
Humphris and Rogers (130)200487United KingdomMean 58 yearsMixedMixedHADS
CWS
Prospective: at 3, 7, 11, 15mPatients who smoked consistently through the study period were significantly younger (by 8y on average) & had higher levels of distress following treatment
Ichikura et al. (131)2016117Japan55.6% were >65Mixed
All hospitalized
MixedHADS
FACT-HN
ProspectiveAge </=65 associated with higher levels of distress at time of hospital admission (p=.03)
Kanatas et al. (132)2012204United KingdomMean 62 yearsMixed
Post-treatment NED
MixedUW-QOL
PCI
Prospective: at least 6w post-treatmentAge</= 64 more likely to report anxiety/depression (p=.02)
Kumar et al. (133)201875India<30 years (n=3), 30-60 years (n=46), >60 years (n=26)Oral cavityMixed (only 7 did not have surgery)DASS-21
HADS
Prospective: baseline, 1m postop, 3m after dischargeDepression scores at diagnosis higher in those 30-60 (vs >60)
Neilson et al. (134)2013101AustraliaMean 63 years (37-85 years)MixedMixedHADSProspective: baseline & 3w & 18m after treatment completionAnxiety scores higher for younger patients
Joseph et al. (135)2013220United KingdomMean 59.5 yearsMixedHad to include RT (definitive or adjuvant)HADS
LENT-SOMA
Prospective: baseline, post-treatmentYounger age associated with higher anxiety before & upon completion of treatment (p=.002 &.004)
Tang et al. (136)2011164TaiwanMean 50.7 yearsMixed cancer types; 35 HNC patientsMixedSDSProspectiveDistress before & after radiation increased more for age 20-39 than age 40-49 and 60-69.
Van Beek et al. (137)2020345The NetherlandsMean 61 years (36-85 years)MixedDefinitive RT +/- chemoHADS
EORTC QLQ-C30 &-H&N35
Prospective: baseline 6w, 3m, 6m, 12m, 18m, 24mYounger patients had a poorer course of anxiety than older, especially between 12m & 24m follow-up (p=.027)
Wang et al. (138)2019211ChinaMean 62 yearsLaryngeal ca scheduled for total or partial laryngectomySurgeryHADSProspective: preoperativeYoungest age group had highest HADS score (p=0.049)
Measures favoring younger
Mccaffrey et al. (139)200724USAMean 73 years (49-82 years)Mixed (all stage III/IV)MixedSCID
DRS
ProspectivePatients >65y experienced more depression than younger pts (p<.04)
Wang et al. (140)2021232ChinaMedian 51 yearsNewly diagnosed NPCRT +/- chemoHADSProspective: Baseline, treatment week 4, post-treatmentIncidence of anxiety & depression in age >40y significantly higher than those <40y at all time points (p=.03 & <.001)
Age not impacting measures
Astrup et al. (141)2015207NorwayMean 61 yearsMixedMixed, but all included RTCES-D
GSDS
LFS
BPI
Prospective: baseline, 1m, 2m, 3m, 6mNo association between age and depressive symptoms
Bjordal and Kaasa (142)1995204NorwayMean 67 yearsMixed site, at least 12m post-treatmentAll received RTGHQ-20
EORTC QLQ-C30
Prospective (treated on two RCTs)No association between distress and age
Bozec et al. (74)201858FranceEvaluated by age </> 65OropharynxSurgery with radial forearm free-flap reconstruction +/- adjuvant RT/chemoHADS
QLQ-C30 & H&N35
VHI
DOSS
Prospective: baseline, at least 1y after surgeryDepression & associated psychological states unrelated to age
Chen et al. (143)2018133USAMedian 56 years (21-97 years)HNSCC, at least 1y disease-freeMixedUW-QOLProspective: baselineNo correlation between prevalence of depression or anxiety with age
De Leeuw et al. (144)2000155The NetherlandsMean 59 yearsOral cavity & larynxSurgery &/or RT, curative intentSSLI
ISSB
SPS
UCL
CLCS
CES-D
EORTC QLQ C30+3
Prospective: baseline, 6m, 12mAge was not a predictor of depressive symptoms
Deng et al. (145)2014356ChinaMean 46.7 yearsNasopharyngealRT or CRT - definitiveDT
HADS
Cross-sectional (n=295) & prospective (n=61)No relationship between distress & age
Derks et al. (146)2005183The Netherlands“Older” (>/=70 years, n=78); “younger” (45-60 years, n=105)Oral cavity
Pharynx (stage II-IV) or larynx (stage III-IV)
MixedEORTC-QLQ-C30
CES-D
UCL
CLCS
Prospective: baseline, 6m, 12mNo differences in depressive symptoms after treatment
Derks et al. (65)2004121The Netherlands51 “Older” (n=51); “younger” (n=70) as defined aboveOral cavity, pharynx (stage II-IV) or larynx (stage III-IV)MixedSemi-structured interview with structured & open questions
CES-D
RSS-12
Prospective: baseline, 1yNo differences in depressive symptoms between groups
Henry et al. (147)2019219CanadaMean 63 years (30-101 years)MixedMixedHADSProspective: baseline, 3m, 6m, 12mNo correlation of anxiety or depression with age
Kim et al. (148)2016241KoreaMedian 61 yearsMixedMixedBDI
EORTC QLQ-C30 & -H&N35
Prospective: baselineNo difference in median age of depressive vs non-depressive patients
Kobayashi et al. (149)200858JapanMean 62 yearsMixed subsite; included new diagnoses & recurrencesSurgeryHADS
RSE scale
Prospective: baseline, 7-10d post-op, 6mNo significant difference in self-esteem by age
Kugaya et al. (150)2000107JapanMean 61 yearsMixed (oral cavity, pharynx, larynx)Mostly surgeryPsychological or psychiatric interview
HADS
Prospective: baselineMean age of patients with & without distress not different
Kunz et al. (151)2021120GermanyMean 62.6 years (range 41-85 years)MixedMixedDTProspective: baselineDistress did not correlate with age
Neilson et al. (152)201075AustraliaMean 62.5 years (37-85 years)MixedMixed but all involved RTHADS
FACT-H&N
Prospective: baseline, ~3w post-treatmentNo significant association between age & post-treatment distress or anxiety
Panwar et al. (153)2018125USAMean 63 yearsMixedMixedQIDS-SRProspectiveNo correlation of depressive symptoms with age
Schell et al. (154)2018100GermanyMean 64.4 yearsOral HNSCC prior to surgical interventionSurgeryDTProspective: baseline (preop)Distress score not correlated with age
Speksnijder et al. (155)2021141The NetherlandsMean 65.6 yearsPrimary oral HNSCCMixed (most surgery)CES-DProspective; multi-center cohort studyAge did not significantly contribute to depression.
Van der schroeff et al. (72)2006266The NetherlandsNot statedMixedMixedQLQ-C30 & -HN35
CES-D
Prospective: baseline, up to 6yNo difference in depressive symptoms between the two age groups 3-6y after start of treatment (45-60y vs >/-70y)
Verdonck-de leeuw et al. (156)200955The NetherlandsMean 63 yearsMixedMixedHADS
QLQ-C30 & -H&N35
Prospective: baseline, first follow-up visitAt diagnosis and follow-up, age not related to distress

Prospective studies reporting distress and age in elderly patients with HNSCC.

BDI-II, Beck Depression Inventory-II; BPI, Brief Pain Inventory; Brief COPE, Brief Coping Orientation to Problems Experienced Inventory; CES-D, Center for Epidemiological Studies Depression; CLCS, Cancer Locus of Control Scale; CWS, Cancer Worry Scale; DASS-21, Depression Anxiety Stress Scales-21; DT, Distress Thermometer; DOSS, Dysphagia Outcome and Severity Scale; FACT-HN, Functional Assessment of Cancer Therapy-Head and Neck module; GHQ-20, General Health Questionnaire-20; GSDS, General Sleep Disturbance Scale;HADS, Hospital Anxiety and Depression Scale; HNCI, Head and Neck Cancer Inventory; ISSB, Inventory of Socially Supportive Behaviors; LENT-SOMA, Late Effects Normal Tissues-Subjective, Objective, Management, Analytic; LFS, Lee Fatigue Scale; LOT-R, Life Orientation Test-Revised; MDRS, Mattis Dementia Rating Scale; PCI, Patient Concerns Inventory; PHQ-9, Patient Health Questionnaire-9; QIDS-SR, Quick Inventory of Depressive Symptomatology-Self Report; QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30; QLQ-H&N35, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Head and Neck module; RSE scale, Rosenberg Self-Esteem scale; RSS-12, Reflux Symptom Score-12; SCID, Structured Clinical Interview for DSM-IV; SDS, Symptom Distress Scale; SF-12 v2, Short Form 12 item (version 2) Health Survey; SSLI, Social Support List Interactions; SPS, Social Provisions Scale; UCL, Utrecht Coping List; UWQOL, University of Washington Quality of Life Questionnaire; VHI, Voice Handicap Index.

The largest prospective study to investigate the relationship between distress and age was reported by Hammerlid et al. in 1999 (127). The HADS was used to provide a measure of distress at baseline (after diagnosis but prior to initiating treatment) and one, two, three, six and 12 months after initiation of treatment in a mixed group of 357 HNC patients receiving various therapies. On average, patients <65 years reported higher levels of distress at diagnosis and at the one year follow up than did older patients. Another large prospective study evaluated a mixed group of 306 HNC patients from the US at their initial clinic appointment, and three- and twelve-months post-diagnosis, using the BDI and the Head and Neck Cancer Inventory. Younger age was associated with worse social disruption at three months (129). Prospective studies showing an association between distress and younger patient age have been reported from investigators in the UK, Japan, India, Australia, Taiwan, China, and the Netherlands (131, 133, 134, 136138). In several studies, younger age is specifically linked to higher rates of anxiety, especially before and during treatment, which some speculate is due to increased fear of recurrence (126, 134, 135, 137).

There are only two prospective studies wherein older patients fared worse with regards to distress, and it is notable that the larger of the two reported on only nasopharyngeal cancer patients in China, with a median age of 51 years. In this study, rates of anxiety and depression in patients over the age of 40 was significantly higher than in those under 40 years at all timepoints; however, the interquartile range was 40-57, and this study is not representative of a broad elderly HNC population. The other prospective study reporting lower distress in younger patients is a very small study from the US reporting on preoperative distress in locally advanced HNC patients. Patients over 65 years were found to experience more depression than younger patients. This study did not utilize commonly utilized instruments and is far too small to draw any useful conclusions (139).

In summary, the preponderance of prospective evidence from a wide range of countries and across most head and neck disease sites and treatments suggests that elderly patients actually fare better with regards to distress as compared to their younger counterparts and that the reasoning for this is likely nuanced. Factors may include mid-life responsibilities more characteristic of younger patients, such as employment, childcare, greater perceived importance of social life, and less earned resilience. As discussed in the following sections, fear of cancer recurrence, pain, fatigue, sleep, body image issues, and post-traumatic stress may also be higher in younger patients. While most of these studies consist of self-reports based on screening tools rather than diagnostic interviews, which is a limitation, the results align with those from the general population; namely, that older people typically report lower levels of distress and anxiety than do younger people (157).

Fear of Cancer Recurrence

Fear of cancer recurrence (FCR) is a common concern reported by cancer survivors, including patients treated for HNC (Table 9). There are a number of methods used to gather information about FCR. FCR severity may be measured using standardized tools like the Fear of Cancer Recurrence Inventory (169, 170) or the Fear of Recurrence questionnaire (166). Concerns about FCR may also be gathered as part of various patient concerns inventories. Irrespective of the method used to gather information on FCR, older cancer survivors report lower levels/rates of FCR on average than younger patients (171). This observation has also been seen in HNC studies where variations in FCR have been analyzed by age (Table 9), with the majority showing an increased vulnerability to FCR in younger patients (158164).

Table 9

AuthorYearnLocationHandling of ageH&N subsiteTreatmentFCR instrumentStudy designFindings
FCR favoring older patients
Mirosevic et al. (158)2019216Slovenia, NetherlandsContinuous
(range 37-85 years)
OCC, 30%
OPC, 34%
HPC, 8%
LC, 25%
CUP, 2%
Pre treatmentCWSBaseline data from a cross-sectional sub study of NET-QUBIC included psychiatric interviewsYounger patients reported higher FCR (β = .203, p<0.001)
Casswell et al. (159)2021136AustraliaContinuous (range 42-87 years)All HPV+ OPCAll RT/CRTFCRI-SFCross-sectional: time since treatment mean 2.97y (range 1.0-5.1y)Younger age worse on UVA (-0.2/year increase, p=0.036)
Rogers et al. (160)2021288United Kingdom<55 vs 55-64 vs 65-74 vs ≥75 yearsOCC, 47%
OPC, 32%
LC, 14%
Other, 8%
Sx alone, 40%
Sx +aRT/CRT, 40%
CRT/RT, 20%
UW-QoL 5-response itemCluster control studyPatients <65 more likely to answer more severe FCR (especially younger females <55)
Ghazali et al. (161)2013189United Kingdom<55 vs 55-64 vs ≥65-74 vs ≥75 yearsOCC, 73%
Pharyngeal, 23%
Sx alone, 59%
Sx + aRT, 32%
RT/CRT, 10%
PCI
FoR questionnaire
Prospective: post treatment (convenience sample, first appt not always patient’s actual first appointment post treatment completion).For first visit:
overall FoR score higher in younger patients and significant FoR in at least one item higher in younger patients
Longitudinal assessment:
About one-third <65 unlikely to encounter significant FoR issues compared to three-quarters of patients ≥65.
Kanatas et al. (162)2015813United KingdomContinuous and <65 yearsOCC, 48%
OPC, 24%
LC, 17%
Other, 9%
CUP, <1%
Sx alone, 49%
Sx +aRT, 34%
CRT/RT, 14%
Unknown, 3%
HNC-PCIAnalysed patients selecting FCR item on PCIPatients selecting FCR were 4-6 years younger;
When analysis first time (n=813) PCI:
Percentage ≥65y: X2 = 33.1, p< 0.001 and ≥75y: X2 = 14.4, p= 0.002
Rogers et al. (163)2016528United Kingdom<55 vs 55-64 vs ≥65 yearsOCC, 34%
OPC, 35%
LC, 20%
Other, 8%
Sx alone, 38%
Sx + aRT, 40%
CRT/RT, 16%
Unknown, 3%
UWQoL single item: “fear of the cancer coming back” on 5-point scale, “I have no fear of recurrence” to “I am fearful all the time that my cancer might return and I struggle with this”
FoR questionnaire
Cross-sectional:Younger patients reported more severe levels of FoR
Rogers et al. (164)2015483United Kingdom<55 – 22%
55-64 – 35%
65-69 – 13%
70-74 – 14%
≥75 – 16%
OCC, 57%
OPC, 21%
Other, 20%
Sx alone, 51%
Sx + aRT, 35%
RT, 10%
HNC-PCIPCI-HN data from follow-up clinics collected from 6 different studies, not consecutive; number of responses ranged from 1-≥4On the PCI, being elderly correlated with fewer items being selected from the psychological, emotional and spiritual wellbeing domain; selecting fear of cancer coming back item reduced with age: 46% vs 42% vs 31% vs 26% vs 20%
Rylands et al. (165)2016448United KingdomContinuousOCC, 40%
OPC, 38%
LC, 22%
Sx alone, 43%
Sx + aRT, 42%
CRT/RT, 15%
FoR questionnaireCross-sectionalAge was inversely correlated with FoR results
FCR not impacted by age
Rogers et al. (166)2010191United KingdomNROCC, 72%
OPC, 21%
Other, 7%
Sx alone, 57%
Sx + aRT, 37%
RT, 7%
HNC-PCI completed at clinic attendance
FoR questionnaire
Cross-sectional: ≥ 6weeks following completion of treatment
Two cohorts: PCI plus UWQoL; PCI plus UwQoL & FoR
Non-significant trend in younger patients selecting FoR item on PCI in cohort 1 (analysis of multi-item questionnaire NR)
Llewellyn et al. (167)200855United KingdomContinuous
(range 23-89)
Subsites NRNR‘Over the past month, how often have you worried about the possibility that cancer might come back?’
Response on 1-5 Likert scale (none of the time to all the time)
Pretreatment and 6-8 month post treatment
Examined longitudinal predictors of FCR in survivors of HNC using Leventhal’s CSM as a framework,
FCR was not related to socio-demographic factors including age
Van Liew et al. (168)2014138USAContinuousNR (only early vs late stage)Sx alone, 38%
RT only, 11%
Combination, 42%
Unknown, 9%
FCRICross-sectionalCurrent age and age at diagnosis were not associated with FCR

Head and neck cancer studies reporting variations in fear of cancer recurrence measures by age.

aRT, adjuvant radiotherapy; CSM, common sense model CUP, carcinoma unknown primary; CWS, Cancer Worry Scale; FCR, fear of cancer recurrence;FCRI, Fear of Cancer Recurrence Inventory; FoR, Fear of Recurrence; HNC, Head and Neck Cancer; HPC, hypopharyngeal cancer; HPV, human papillomavirus; LC, laryngeal cancer; NR, not recorded; OCSCC, oral cavity cancer; OPC, oropharyngeal cancer; PCI, Patient Concerns Inventory RT/CRT, radiotherapy/chemoradiotherapy; SF, short form; Sx, surgery; UVA, univariate/variable analysis; UW-QoL, University of Washington Quality of Life questionnaire.

Concerns about cancer recurrence (perhaps fear of progression) may begin early on the cancer journey, and age-related differences may be observed even before treatment has commenced. Mirosevic et al. reported FCR outcomes in 216 newly diagnosed HNC patients using the 8-item Cancer Worry Scale (158). FCR scores were higher in younger patients, and age, along with baseline HADS anxiety scores were the strongest predictors of baseline FCR. As shown in Table 9, many studies have included substantial proportions of patients treated for oral cavity cancer with surgery alone. Irrespective of study design, younger patients appear more vulnerable, with the oldest patients (≥75 years) reporting low or lower rates of FCR (162, 164). In a cross-sectional cohort of 136 patients with HPV-associated oropharyngeal cancer treated with definitive (chemo)radiotherapy Casswell et al. measured FCR using the FCRI-short form (which assesses the severity domain of the larger FCRI version). In this study, age was analyzed as a continuous variable, and it is interesting to note that even with this favorable HNC cohort harboring a typically low risk of recurrence (given most had had a complete response to treatment and the mean time since treatment completion was 3 years) that older patients continued to report lower rates of FCR.

Body Image Distress in Older Patients With HNSCC

Body image studies in HNC have mostly been undertaken in samples of patients undergoing major surgery for their cancer, as detailed in Table 10. In summary, evidence of an association between age and body image distress is weak but limited cross-sectional and retrospective data suggest similar or less severe body image distress in older HNC patients (172175). Further high-quality research is needed in this area.

Table 10

AuthorYearNo.LocationAgeH&N SubsiteTreatmentInstrumentStudy DesignFindings
Body Image
Chen et al. (172)2020154ChinaMostly men, 40-65 yearsMostly thyroid, oral cavity, larynxSurgery within past monthBIS
HADS
PSSS
SCSQ
Cross-sectionalYounger patients (<40y) had significantly higher BIS score (more dissatisfaction), which is associated with higher anxiety.
Clarke et al. (173)201449United KingdomMean 60.4 yearsHNSCC (stage III-IV, recurrent, or radiation failure)MixedDAS24
HADS
Cross-sectional: baseline and 9mNo correlation between age & DAS-24 score
Vilaseca et al. (174)200649USAMean 62.7 years (44-82 years)LarynxTotal laryngectomyUW-QOLCross-sectionalYounger patients more likely to express dissatisfaction with appearance
Zebolsky et al. (175)2021103USAMedian 66 yearsMixed, mostly oral cavity and cutaneousAll involved microvascular reconstructionARPD
SF scales of the FACE-Q
Retrospective: median time of follow-up at time survey completed 13.5mAge not significantly associated with ARPD or SF scores
Pain
Cramer et al. (176)2018175USAMedian 65 yearsHNC survivors >/=1 y after diagnosisMixedPain and QOL assessed with multiple instrumentsRetrospectivePatients <55y more likely than older patients to develop pain (odds ratio of 0.38 for 75+ vs <55)
Moye (177)2014170USAMean 64.6 years (27-88 years)HNC, esophageal, gastric, or colorectal cancer from the VA
(40% H&N)
MixedPROMIS
PHQ-9
Prospective: 6m, 12m, & 18mAt 6m post-diagnosis, younger adults described higher levels of pain & of pain intensity.
Hassanein et al. (178)200168United KingdomMedian 58 yearsOral cavity, oropharyngeal, maxillary sinus cancer, 6m to 6y post-treatmentMixedUW-QOL
HADS
MAC-Q
SSQ6
RetrospectiveYoung pts (≤60) had more functional problems, highly significant for swallowing & shoulder pain, and significant for pain.
Fatigue/Sleep
Hickok (179)2005372USAMean age of HNC patients 61 yearsReceiving RT for cancer (HNC, n=23)RTIn-house 12-item symptom inventoryProspective: inventory completed weekly for 5 weeks during RTAge not predictive of fatigue severity at any time point
Rogers et al. (180)200858USAMean 60 yearsMixedMixedFSI
PSQI
FACT-Cog
Cross-sectionalFatigue, sleep dysfunction, poorer cognitive function all associated with younger age (all statistically significant)
Santoso et al. (181)2020560The NetherlandsMean 63 yearsMixed, patients on prospective NET-QUBIC studyMixedPSQICross-sectional, multi-centerYounger age significantly associated with poor sleep (p=.049)
PTSD
Holtmaat et al. (182)201674The NetherlandsMedian 61.2 years (41-83 years)HNC survivors with psychological distress (HADS-Anxiety or -Depression >7)MixedPTGICross-sectionalAge not significantly related to PTGI score
Kangas et al. (183)200582United KingdomNot statedNew diagnosis of head & neck (n=56) or lung cancerMixedASDI
EORTC QLQ-C30
Mini-MAC
PDEQ
BDI-II
STAI-Y
PTCI
DUKE-SS
Prospective: assessed for acute stress disorder at baseline, and for PTSD at 6 months post-diagnosisIncidence of PTSD higher in younger patients (mean age for PTSD 49, vs 61 for no PTSD, p <.05)
Moschopoulou et al. (184)201893United KingdomMean 66 yearsHNC in follow-up stage and at least 2y out from diagnosisMixedHADS
ESSI
ALTTIQ
DAS24
QLQ-C30
PCL-C
Cross-sectionalNegative association between PCL-C score and age (younger age is associated with posttraumatic stress syndrome)
Posluszny et al. (185)201442USAMean 55 yearsNewly diagnosed HNC ptsMixedPCL-CProspective study of dyads (patient plus partner)Age not related to PCL score
Richardson et al. (186)201691New ZealandNot statedMixedMixedFACT-H&N
GHQ-12
PSS-SR
Brief COPE
Prospective; baseline & 6mAge not significantly correlated with PTSD at diagnosis or follow-up

Studies reporting on body image, pain, fatigue/sleep, and post-traumatic stress.

ALTTIQ, Assessment of Life Threat and Treatment Intensity;ARPD, Appearance-Related Psychosocial Distress; ASDI, Acute Stress Disorder Inventory; BDI-II, Beck Depression Inventory-II; BIS, Body Image Scale; Brief COPE, Brief Coping Orientation to Problems Experienced Inventory DAS24, Derriford Appearance Scale-24; DUKE-SS, Duke-UNC Functional Social Support Scale; ESSI, ENRICHD Social Support Inventory; FACT-Cog, Functional Assessment of Cancer Therapy-Cognitive; FACT-H&N, Functional Assessment of Cancer Therapy-Head and Neck module; FSI, Fatigue Symptom Inventory H&N, head and neck; GHQ-12, General Health Questionnaire-12; HADS, Hospital Anxiety and Depression Scale; HNC, head and neck cancer; HNSCC, head and neck squamous cell carcinoma; MAC-Q, Memory Complaint Questionnaire; Mini-MAC, Mini-Mental Adjustment to Cancer; NET-QUBIC, Netherlands Quality of Life and Biomedical Cohort; PCL-C, PTSD Checklist-Civilian; PDEQ, peritraumatic dissociative experiences questionnaire PHQ-9, Patient Health Questionnaire-9; PROMIS, Patient Reported Outcomes Measurement Information System; PSSS, Perceived Social Support Scale; PSQI, Pittsburgh Sleep Quality Index; PSS-SR, Posttraumatic Symptom Scale Self-Report versionPTCI, Posttraumatic Concerns Inventory; PTGI, Post-Traumatic Growth Inventory; QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30; SCSQ, Simplified Coping Style Questionnaire; SF, Social Functions; SI, Symptom Inventory; SSQ6, Social Support Questionnaire-Short Form; STAI-Y, State-Trait Anxiety Inventory-Y;UW-QOL, University of Washington Quality of Life Questionnaire; VA, Veterans’ Affairs.

Fatigue and Sleep in Older Patients With HNSCC

There is a paucity of data on sleep quality in HNC patients; however, insight into sleep quality would likely help healthcare providers better support their patients. Sleep disturbance and fatigue have been shown to contribute significantly to depressive symptoms, and sleep is unique as it is an often treatable risk factor (141). Tools used to assess sleep and fatigue in HNC patients include the Pittsburgh Sleep Quality Inventory (PSQI), Fatigue Symptom Inventory, Lee Fatigue Scale, and General Sleep Disturbance Scale (GSDS).

Table 10 outlines studies reporting on fatigue and sleep in head and neck cancer patients. Hickok et al. prospectively administered a one-page symptom inventory to 372 patients weekly for five weeks during radiotherapy. Of note, this included patients with all types of cancer and only 23 had HNC. Mean age of the HNC patients was 61 years, and age was not predictive of fatigue severity at any time in this study (179). Other studies are cross-sectional in design but have the advantage of being limited to head and neck cancer and, like most of the other domains reviewed, they appear to show an association between younger age and poor sleep quality and fatigue (180, 181). As with body image distress, more high-quality research would be helpful in investigating this relationship further.

Pain in Older Patients With HNSCC

Pain is experienced as one of the most impactful sources of distress in cancer survivors and has been linked to poorer outcomes and decreased QoL (177). Most of the literature on pain and HNC indicates that younger patients experience higher levels of pain than older patients. Relevant studies are reported in Table 10. In summary, one prospective trial conducted using the PROMIS scale in a Veterans Administration Hospital population showed that at six months post-diagnosis, younger adults (64 years and younger) described significantly higher levels of pain and of pain intensity as compared to older adults (≥65). It is notable that this was a mixed population of cancer patients, with 40% having HNC (177).

Two retrospective papers show similar trends, with younger patients experiencing more pain. Interesting findings from these studies include that the incidence of pain among survivors was as high as 45.1% at a median of 6.3 years since treatment completion, and that pain was the third-most important issue identified by survivors, after swallowing and saliva. Additionally, patients with pain were significantly more likely to report issues with anxiey and mood (176). The findings also suggest that younger patinets may have more functional problems, including dysphagia and shoulder function (178).

This is an interesting observation with many possible confounders, and future research efforts may look to focus on understanding this association and strategies to help support younger patients affected by HNC.

Post-Traumatic Stress in Elderly HNC Patients

As with other factors influencing distress, the literature evaluating the relationship between PTSD and age in HNC patients is mixed, with some showing no difference in rates, and some showing higher incidence in younger patients (Table 10). There have been two similarly powered prospective studies, with contradictory findings regarding an asssociation between PTSD and age (183, 186). Cross-sectional studies, as well as one small prospective study of patient-partner dyads, have shown mixed results (182, 184, 185). In summary, the literature suggests either no association between age and PTSD, or a trend toward higher rates in younger patients.

Differences in Coping Styles

Coping refers to the ways in which people respond to and behave during stressful events, and it is likely to influence how one evaluates his or her quality of life (146). Research suggests older people adapt better to cancer because serious illness is more common and expected with increasing age and their experience of physical decline may be less dramatic. Younger people also often have more stage of life-related stressors like child-rearing and employment (146).

Pre- and post-treatment depression and anxiety have been linked to ineffective coping styles such as helplessness/hopelessness, fatalism, and avoidant coping (128). Some authors have noted that although depression and anxiety are more easily measured than coping styles, patient coping strategies may be more amenable to intervention (128). Notably, coping styles seem to vary quite predictably with age in samples of HNC patients (Table 11).

Table 11

AuthorYearNo.LocationHandling of AgeH&N subsiteTreatmentInstrumentStudy DesignFindings
Aarstad et al. (187)201296NorwayMean for twice-interviewed patients 56 yearsHNC survivors <80 years oldMixedCOPE
BDI
Cross-sectionalAge not significantly associated with coping style
Aarstad et al. (188)2011139NorwayMean 60 yearsHNC survivors at least 12 months NED <80 years oldMixedCOPECross-sectionalAge not significantly associated with coping style
Derks et al. (146)2005183The Netherlands“Older” (≥70 years, n=78)
“Younger” (45-60 years, n=105)
Oral cavity, pharynx (stage II-IV) or larynx (stage III-IV)MixedEORTC-QLQ-C30
CES-D
UCL
CLCS
Prospective; baseline, 6m, 12mOlder & younger patients use different coping & locus of control strategies. Younger patients used more active coping strategies & perceived more internal control. Older patients tended to use religion.
Horney et al. (128)2010103United KingdomMean 63 yearsMixedMixedHADS
LOT-R
Brief COPE
SF-12 v2
Cross-sectionalYounger age significantly associated with negative coping styles (“helplessness”, denial, venting, substance abuse, behavioral disengagement)
Ichikura et al. (189)2017116JapanNot statedHNC outpatient survivors who had completed treatment and were >20 years oldMixedBrief-COPE
BDI-II
Cross-sectionalAge >/=65 associated with “resigned” coping style (vs dependent or problem-focused)
Verdonck-de leeuw et al. (190)200741The NetherlandsMean 59 yearsMixed, at follow-up clinicMixedHADSCross-sectional, administered to patient-spouse pairsTotal HADS score not significantly related to age but is significantly related to passive coping style (which can be associated with more pessimism, worry, & distress) & non-expression of emotions

Studies reporting on coping styles.

BDI-II, Beck Depression Inventory-II; Brief COPE, Brief Coping Orientation to Problems Experienced Inventory;HADS, Hospital Anxiety and Depression Scale; CES-D, Center for Epidemiologic Studies Depression scale; LOT-R, Life Orientation Test-Revised; QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30; SF-12 v2, Short Form 12 item (version 2) Health Survey UCL, Utrecht Coping List; CLCS, Cancer Locus of Control Scale.

One prospective study showed that older and younger patients use different coping and locus of control strategies, with younger patients using more active coping strategies and perceiving more internal control, and older patients tending to use religion. These differences in coping styles did not significantly impact QoL or depressive symptoms, but avoidant coping style was associated with worse depressive symptoms and QoL regardless of age group (146).

One retrospective study showed that younger age is significantly associated pretreatment anxiety and with negative coping styles such as helplessness, denial, venting, substance abuse, and behavioral disengagement (128). Another showed that older patients tended to use a “resigned” coping style (versus dependent or problem-focused). The dependent-coping pattern, which includes smoking, drinking, seeking support and engaging self-distraction, was found to be the most common style and was also the most likely to be associated with depression (189).

There are other studies, in contrast, that have shown no association between age and coping style, most notably, the Norweigan studies by Aarstad et al. (187, 188). Again, this area would benefit from further exploration.

Suicidality in Older Patients With HNSCC

At the extreme end of unrecognized or poorly managed psychosocial distress are self-inflicted injuries including suicide. Patients with any cancer diagnosis have been reported to have higher risks of suicide (191193) or non-fatal self-injury (NFSI) compared to the general population, and patients with HNC may harbour even higher rates compared to most other types of cancer (191, 193196). Other factors such as increasing age, social supports and a history of mental health have also been associated with an increased suicide risk (197).

Zaorsky et al. compared rates of suicide outcomes in cancer patients via the US-based SEER database from 1973 to 2014 (191). Compared to the general population, the relative risk of suicide was highest for those patients diagnosed with head and neck, lung, and testicular cancer, as well as Hodgkin lymphoma. The standardized mortality ratio (SMR) for HNC patients was highest in the first year after diagnosis and decreased with time from the initial diagnosis. Across the entire cancer cohort, elderly, white men with localized cancer who were not married were at highest risk. In a SEER study focusing primarily on patients with HNC (including thyroid), Kam et al. reported an adjusted (age, sex, race) suicide rate of 37.9 per 100 000 person-years, corresponding to a SMR of 3.21 (95% CI 2.18-4.23). Across all HNC subsites, older patients (60-79 years and >80 years) had the highest SMR. All of the HNC subsites, except for thyroid, had a higher risk of suicide than the general population, with those patients diagnosed with hypopharynx having the highest risk (SMR 13.91, 95% CI, 11.78-16.03). There was a decline in SMR over time for most of the subsites, though for all but thyroid and nasal cavity/sinuses, the risk exceeded that of the general population, while those with NPC had a persistently elevated and high risk even 15 to 30 years after their diagnosis.

In a Korean study, Choi et al. reported higher suicide risk amongst cancer patients older than 60 years of age compared to sampled population data (includes ~10% of the entire population (193). Similar to the Zaorsky et al. study, the risk of suicide was highest in the first year after any cancer diagnosis, accounting for 34.9% of all cases (median time to suicide was 1.74 years). For those patients diagnosed with a HNC, the adjusted hazard ratio was 2.28 (95% CI 1.47-3.54) which was amongst the highest risk for any cancer type.

Unmet Needs in Elderly Patients With HNSCC

Although various unmet needs tools are available for use in cancer populations, their content and structure is highly variable. Individual items and needs domains covered may range from physical and psychological needs to informational needs. Needs domains may also include, but are not limited to, nutritional, dental, financial, and sexual needs. Shunmugasundaram et al. recently conducted a systematic review comparing the content of self-reported unmet needs instruments in head and neck cancer populations, concluding that the PCI was the most comprehensive of the available tools, covering all twelve specified needs included in the conceptual framework of unmet needs developed by the research team (198). This is perhaps not surprising given it was the only unmet needs instrument which was developed specifically in a head and neck cancer population and has undergone continual refinement since its initial development. Studies of HNC patients including unmet needs tools are summarized in Table 12.

Table 12

AuthorLocationNo.Age(range)Head Neck SubsiteTreatmentInstrumentDomains coveredStudy design Assessment TimeVariation – No. needsVariation - specific needs
Giuliani et al. (199)Canada158Median 64 years
(19-89 years)
OC, 29%
OPC, 17%
HPC/LC, 17%
NPC, 5%
Other 33%
Sx, 22%
Sx + aRT/CRT, 35%
RT/CRT, 40%
CaSun35 items, 5 domains:
Existential, Survivorship, Comprehensive Cancer Care, Information, Quality of Life, and Relationships
Cross-sectionalDiagnosis to follow-up
(68% ≥6m post treatment)
Older less unmet needsNR
Henry et al. (200)Canada127Mean 61 yearsOC, 35%
OPC, 8%
LC, 21%
Thyroid, 8%
Other, 28%
None, 2%
Sx alone, 15%
Sx + aRT/CRT, 41%
RT/CRT, 43%
SCNS-SF3434 needs items, 5 domains: Psychological,
Health system and information, Physical
and daily living, Patient care and support, and Sexuality
Cross-sectionalPost-treatment (49% ≥1y)No differences by ageNR
Henry et al. (201)Canada145Mean 63 yearsOC, 16%
OPC, 44%
HPC, 1%
LC, 14%
NPC, 3%
Other, 14%
Unknown, 9%
Any:
Sx, 36%
RT, 86%
CT, 67%
SCNS-SF3434 needs items, 5 domains: Psychological,
Health system and information, Physical
and daily living, Patient care and support, and Sexuality
Factor analysis determined 3 dimensions: 1. psychological and physical and daily living domain; 2. health system and information, patient care and support domain; and 3. sexuality domain
Prospective: reported post-treatment outcomes3 months post-treatmentNo differences by ageOnly the sexuality domain varied by age
Wells et al. (202)Scotland319Mean 65 years (27-91 years)OCC, 34%
LC, 33%
OPC, 20%
NR, 13%
Sx alone, 27%
Majority “combination therapy”
PCI45 concerns items, no domains *Cross-sectional postalPost treatment
(69% ≥ 1y)
Younger patients more concerns:
(Mean)
<45 - 11.5
45-54 – 11.6
55-64 – 10.1
65-74 – 7.6
≥75 – 7.9
NR
Rogers et al. (164)United Kingdom483Median 63 years (56-72 years)OCC, 57%
OPC, 21%
Other, 20%
Sx alone, 51%
Sx + aRT, 35%
RT, 10%
PCI57 concerns items;
Physical function and wellbeing, Treatment-related, Social care and social wellbeing, Psychological, Emotional and Spiritual wellbeinga
PCI data from follow-up clinics collected from 6 different studies, not consecutive; number of responses ranged from 1-≥4Post treatmentNo difference in total concernsDecrease in FCR from 46% (<55) to 20% (≥75)
Older patients more frequently selected bowel habits, constipation, diarrhoea, coughing
and memory
Older patients selected fewer items in the
psychological, emotional and spiritual wellbeing domain
Ghazali et al. (203)United Kingdom674Mean 64 yearsOCC, 50%
Pharynx, 25%
LC, 17%
Other, 6%
Sx alone - 50%
Sx + aRT, 33%
CRT, 14%
Unknown, 3%
PCI57 concerns items;
Physical function and wellbeing, Treatment-related, Social care and social wellbeing, Psychological, Emotional and Spiritual wellbeing *
PCI data for first time completersPost-treatment (Median 32m, range 14-58m)NROlder patients less likely to select items from the:
1. psychological, emotional wellbeing and spiritual domain; and
2. Social care and wellbeing domain
O’Brien et al. (204)Ireland583<60 35%
60-69 37%
≥70 27%
OCC, 47%
Pharyngeal, 19%
LC, 30%
Unknown, 4%
Any:
Sx, 69%
RT, 64%
CT, 22%
SCNS-SF3434 needs items, 5 domains:
Psychological,
Health system and information, Physical
and daily living, Patient care and support, and Sexuality
Cross-sectionalPost-treatment (50% > 5y)NROlder patients reported fewer items in each domain
Manne et al. (205)New Jersey92Mean 62 (33-79)OCC, 62%
OPC, 38%
Any: (self-reported)
Sx, 66%
RT, 84%
CT, 65%
Shortened version - SCNS-SF34Only 25 items, 5 domains:
Psychological,
Health system and information, Physical
and daily living, Patient care and support, and Sexuality
Cross-sectionalPost-treatmentAge not associated with total support needs;Age not associated with information needs
Chen et al. (206)Taiwan112Mean 53 (27-80)OCC, 100%All surgeryChinese version SCNS-SF3434 needs items, 5 domains:
Psychological,
Health system and information, Physical
and daily living, Patient care and support, and Sexuality
Cross-sectionalPost-surgery (10-14 days)Older age associated with decreasing overall needsOlder age associated with decreasing sexual needs, but not other domains
Lee et al. (207)USA342Mean 56Tongue, 48%
Tonsil, 18%
Other 30% %
OPC, 18%
Any:
Sx, 71%
RT, 84%
CT, 58%
SUNS89 items, 5 domains:
Information, Access and continuity of care, Emotional health, Relationships, and Financial concerns.
Cross-sectionalPost-treatment (>3m)NROlder age associated with less relationship and emotional needs

Studies reporting variations in unmet needs by age in HNC patients.

aRT/CRT, adjuvant radiotherapy/chemoradiotherapy; CaSUN, Cancer Survivors’ Unmet Needs Measure; CT, chemotherapy; FCR, fear of cancer recurrence; HPC, hypopharyngeal cancer; LC, laryngeal cancer; NPC, nasopharyngeal cancer; NR, not reported; OCC, oral cavity cancer; OPC, oropharyngeal cancer; PCI, patient concerns inventory; RT/CRT, radiotherapy/chemoradiotherapy; SCNS-SF34, Supportive Care Needs Survey–Short Form; SUNS, Survivors Unmet Needs Survey; Sx, surgery.

a

The PCI has evolved over time with additional items and grouping into domains (164, 208).

Almost all of these studies focused on patients who had emerged from the acute post-treatment period with exception of the Canadian study by Giuliani et al. which included patients from diagnosis through to survivorship and that by Chen which evaluated patients shortly after they had undergone surgery (206). The survivors included in many of these studies are quite heterogenous, as has been seen in many of the QoL and psychosocial distress reports with only the study by Chen et al. focusing on patients with oral cavity cancer (206). Despite variability in the instruments used, the available evidence suggests that older patients report fewer unmet needs than younger patients. In those studies which report a summed overall assessment of unmet needs, most have shown a lower burden in older patients (199, 202, 206) or no age-related differences at all (164, 200, 201, 205). For individual domains, older patients generally report less unmet needs, including in the sexuality domain (201, 206), or domains assessing psychological/emotional or spiritual needs (164, 203, 204, 207).

Novel Approaches

Biological Age

Recently, Xiao et al. reported associations between epigenetic age acceleration (EAA), survival and HRQL in HNC patients (22). EAA )describes discordance between the chronological age of an individual and their “epigenetic age”; EAA’s can be both positive, where the epigenetic age is greater than the patients’ chronological age, or more simply where aging has been accelerated, and negative where the reverse is seen, indicating a slower aging process. In this sample, they identified clinical variables associated with increased EAA, which was associated with worse survival outcomes. However, they also analyzed longitudinal variations in the FACT-H&N. Using a multivariable generalized estimating equation, and controlling for covariates, patients with a negative EAA had higher FACT-H&N total score over, indicating better QoL, than those with a positive EAA. The estimated score difference was 10.6 points (p<0.001), which is in excess of a commonly cited MCID (98). These are intriguing results, but how best to utilize these measures in clinical practice and how to incorporate them into complex treatment decision-making pathways and counselling will require additional research.

Comprehensive Geriatric Assessment

Across the oncology landscape, interest is increasing in the use of comprehensive geriatric assessments (CGAs) to aid clinical decision making in older individuals with cancer. The CGA has been defined as “a multidimensional, interdisciplinary diagnostic process focusing on determining an older person’s medical, psychosocial, and functional capabilities to develop a coordinated and integrated plan for treatment and long-term follow-up” (209, 210). The International Society of Geriatric Oncology have recommended a core set of domains to assess in a CGA, including functional status, fatigue, medical comorbidities, cognitive capacity and underlying mental health issues, social status and the anticipated degree of social support, nutritional status and the presence of any geriatric syndromes, which is a term encompassing many issues of the elderly including falls, delirium and dementia, osteoporosis and polypharmacy, amongst others (210). In HNC populations, the CGA may be more adept at uncovering impairments beyond that of the multi-disciplinary team; it has also been associated with the length of post-operative inpatient stays and the rates of surgical complications and successful completion of radiotherapy (211214). Deficits in some of the CGA domains may predict more significant declines in global QoL (215) or other HRQL domains (214) after treatment in HNC patients. The implementation and use of CGA in routine clinical practice is, however, resource intensive and while a comprehensive assessment of every older patient being considered for curative-intent HNC treatment would no doubt lead to many opportunities for pre-treatment optimization, how best to incorporate a CGA into routine practice would need considerable resource and multi-disciplinary investment at a local or institutional level.

Limitations

This narrative review provides an overview of findings from studies investigating health and wellbeing outcomes and unmet needs in older and elderly patients with HNC and HNSCC and contrasts them to outcomes reported in younger HNC patients. Of the available studies, there are several limitations hampering the ability to draw firm conclusions. Most notably the data is hindered by a lack of consensus in defining the threshold for an older HNC patient. These studies which largely included patients treated with radical treatment also represent the outcomes for a biased population of robust older patients and their outcomes are likely not generalizable to all older patients with HNC, particularly those who may be more frail. It is also worth considering that these studies did not include detailed information about the treatments received, and whether older patients may have undergone reduced intensity treatment to accommodate their age, such as alterations in surgical fields, radiation volumes or chemotherapy dosing. The available studies also vary widely in the different PROs used, the methodologies used in their application and the statistical methods with which they have been analyzed and interpreted. Future studies and high-quality research will hopefully add to our understanding and avoid some of the aforementioned limitations. Well-defined secondary analyses from prospective phase II or III studies where older patients are included would be a welcome addition to the literature. In this review, where possible we have focused on those studies including only HNSCC, however, this was not always possible particularly with the lesser-studied psychosocial distress outcomes. However, despite their histological similarities, HNSCC encompasses a diverse range of tumors, including tumors with different etiology (HPV or smoking-related), primary sites and treatment, factors which may all impart different HRQL and psychosocial challenges for individual HNC patients. Interpretation outcomes from the various studies included in this review was frequently hampered by a reliance on statistical inferences rather than focusing on differences that would be clinically relevant, a theme which echoes throughout most of the PRO literature. Future studies of age-related changes would benefit from taking into account what is already known about changes over the life course in the general population. This would further our understanding of cancer- and treatment-related issues in younger and older patients. Future research exploring variations in age-related outcomes in HNC populations will need to focus on these challenges to draw more meaningful conclusions for our patients.

Conclusions and Future Directions

While there are many limitations to the available data this review should be reassuring when considering intensive treatment in the older HNC and HNSCC population. In synthesizing the varied health and wellbeing outcomes included in this report, when undergoing curative intent protocols, older patients have tended to demonstrate more resilience in HRQL and psychosocial outcomes when compared to their younger counterparts, with the caveat the older patients included in most of these studies were considered robust enough to treat with radical treatment. While refining optimal survivorship models will remain across the continuum of patients presenting with HNC, these findings suggests that we should be in fact more aware of the support that younger HNC patients may need across multiple HRQL and psychosocial distress domains following HNC treatment, despite their perceived physical robustness. Future research efforts in reporting age-related variations in HRQL, psychosocial distress and unmet needs will need to work towards harmonizing the definition of the older HNC patient, narrow the research question in more homogenous HNC populations and investigate novel approaches to measure biological rather than chronological age.

Publisher’s Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Statements

Author contributions

LM and CH designed the concept of the submitted manuscript, were responsible for data acquisition and wrote the first draft. All authors (LM, CH, KG, and DR) were involved in the interpretation of the data included and in drafting and revising the first draft. All authors have provided approval for publication of the included content.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

  • 1

    BrayFFerlayJSoerjomataramISiegelRLTorreLAJemalA. Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin (2018) 68(6):394424. doi: 10.3322/caac.21492

  • 2

    NCCN Clinical Practice Guidelines in Oncology. Head and Neck Cancers, Version 2.2021 (2021).

  • 3

    HanasogeSMaglioccaKRSwitchenkoJMSabaNFWadsworthJTEl-DeiryMWet al. Clinical Outcomes in Elderly Patients With Human Papillomavirus-Positive Squamous Cell Carcinoma of the Oropharynx Treated With Definitive Chemoradiation Therapy. Head Neck (2016) 38(6):846–51. doi: 10.1002/hed.24073

  • 4

    SzturzPVermorkenJB. Treatment of Elderly Patients With Squamous Cell Carcinoma of the Head and Neck. Front Oncol (2016) 6:199. doi: 10.3389/fonc.2016.00199

  • 5

    SmithBDSmithGLHurriaAHortobagyiGNBuchholzTA. Future of Cancer Incidence in the United States: Burdens Upon an Aging, Changing Nation. J Clin Oncol (2009) 27(17):2758–65. doi: 10.1200/JCO.2008.20.8983

  • 6

    RomanBRAragonesA. Epidemiology and Incidence of HPV-Related Cancers of the Head and Neck. J Surg Oncol (2021) 124(6):920–2. doi: 10.1002/jso.26687

  • 7

    TotaJEBestAFZumstegZSGillisonMLRosenbergPSChaturvediAK. Evolution of the Oropharynx Cancer Epidemic in the United States: Moderation of Increasing Incidence in Younger Individuals and Shift in the Burden to Older Individuals. J Clin Oncol (2019) 37(18):1538–46. doi: 10.1200/JCO.19.00370

  • 8

    Soto-Perez-de-CelisELiDYuanYLauYMHurriaA. Functional Versus Chronological Age: Geriatric Assessments to Guide Decision Making in Older Patients With Cancer. Lancet Oncol (2018) 19(6):e305–16. doi: 10.1016/S1470-2045(18)30348-6

  • 9

    ØrumMGregersenMJensenKMeldgaardPDamsgaardEMS. Frailty Status But Not Age Predicts Complications in Elderly Cancer Patients: A Follow-Up Study. Acta Oncol (2018) 57(11):1458–66. doi: 10.1080/0284186X.2018.1489144

  • 10

    FerriASegnaEVarazzaniACopelliCValsecchiSDell'Aversana OrabonaGet al. Free Flap Head and Neck Reconstruction in the Elderly: What is the Impact on Quality of Life? Acta Otorhinolaryngol Ital (2019) 39(3):145–9. doi: 10.14639/0392-100X-2149

  • 11

    HorsleyPJPereraLVenessMJStevensMJEadeTNBackMet al. Outcomes for Elderly Patients 75 Years and Older Treated With Curative Intent Radiotherapy for Mucosal Squamous Cell Carcinomas of the Head and Neck. Head Neck (2020) 42(1):2532. doi: 10.1002/hed.25969

  • 12

    WardMCReddyCAAdelsteinDJKoyfmanSA. Use of Systemic Therapy With Definitive Radiotherapy for Elderly Patients With Head and Neck Cancer: A National Cancer Data Base Analysis. Cancer (2016) 122(22):3472–83. doi: 10.1002/cncr.30214

  • 13

    SzturzPBossiPVermorkenJB. Systemic Treatment in Elderly Head and Neck Cancer Patients: Recommendations for Clinical Practice. Curr Opin Otolaryngol Head Neck Surg (2019) 27(2):142–50. doi: 10.1097/MOO.0000000000000526

  • 14

    AminiAJonesBLMcDermottJDSerracinoHSJimenoARabenDet al. Survival Outcomes With Concurrent Chemoradiation for Elderly Patients With Locally Advanced Head and Neck Cancer According to the National Cancer Data Base. Cancer (2016) 122(10):1533–43. doi: 10.1002/cncr.29956

  • 15

    Santana-DavilaR. Head and Neck Cancer in Elderly Patients: What to Do When Data Are Limited? J Oncol Pract (2018) 14(9):549–50. doi: 10.1200/JOP.18.00480

  • 16

    World Health Organisation. Ageing (2021). Available at: https://www.who.int/health-topics/ageing.

  • 17

    Wikipedia. Retirement Age (2021). Available at: https://en.wikipedia.org/wiki/Retirement_age.

  • 18

    BalducciL. Management of Cancer in the Elderly. Oncol (Williston Park) (2006) 20(2):13543; discussion 44, 46, 51-2.

  • 19

    WheelwrightSDarlingtonASFitzsimmonsDFayersPArrarasJIBonnetainFet al. International Validation of the EORTC QLQ-ELD14 Questionnaire for Assessment of Health-Related Quality of Life Elderly Patients With Cancer. Br J Cancer (2013) 109(4):852–8. doi: 10.1038/bjc.2013.407

  • 20

    PignonJPle MaitreAMaillardEBourhisJGroupM-NC. Meta-Analysis of Chemotherapy in Head and Neck Cancer (MACH-NC): An Update on 93 Randomised Trials and 17,346 Patients. Radiother Oncol J Eur Soc Ther Radiol Oncol (2009) 92(1):414. doi: 10.1016/j.radonc.2009.04.014

  • 21

    XiaoCBeitlerJJPengGLevineMEConneelyKNZhaoHet al. Epigenetic Age Acceleration, Fatigue, and Inflammation in Patients Undergoing Radiation Therapy for Head and Neck Cancer: A Longitudinal Study. Cancer (2021) 127(18):3361–71. doi: 10.1002/cncr.33641

  • 22

    XiaoCMillerAHPengGLevineMEConneelyKNZhaoHet al. Association of Epigenetic Age Acceleration With Risk Factors, Survival, and Quality of Life in Patients With Head and Neck Cancer. Int J Radiat Oncol Biol Phys (2021) 111(1):157–67. doi: 10.1016/j.ijrobp.2021.04.002

  • 23

    ListMARutherfordJLStracksJPauloskiBRLogemannJALundyDet al. Prioritizing Treatment Outcomes: Head and Neck Cancer Patients Versus Nonpatients. Head Neck (2004) 26(2):163–70. doi: 10.1002/hed.10367

  • 24

    ListMAStracksJColangeloLButlerPGanzenkoNLundyDet al. How Do Head and Neck Cancer Patients Prioritize Treatment Outcomes Before Initiating Treatment? J Clin Oncol (2000) 18(4):877–84. doi: 10.1200/JCO.2000.18.4.877

  • 25

    WindonMJD'SouzaGFarajiFTroyTKochWMGourinCGet al. Priorities, Concerns, and Regret Among Patients With Head and Neck Cancer. Cancer (2019) 125(8):1281–9. doi: 10.1002/cncr.31920

  • 26

    BrotherstonDCPoonILeTLeungMKissARingashJet al. Patient Preferences for Oropharyngeal Cancer Treatment De-Escalation. Head Neck (2013) 35(2):151–9. doi: 10.1002/hed.22930

  • 27

    OttoRADobieRALawrenceVSakaiC. Impact of a Laryngectomy on Quality of Life: Perspective of the Patient Versus That of the Health Care Provider. Ann Otol Rhinol Laryngol (1997) 106(8):693–9. doi: 10.1177/000348949710600815

  • 28

    DimovskaEOClibbonJJMoncrieffMDHeatonMJFigusA. Microsurgical Reconstructions for Head and Neck Cancers in Elderly Aged >80 Years: An Analysis of Surgical Outcomes and Quality of Life. Ann Surg Oncol (2016) 23(5):1684–92. doi: 10.1245/s10434-015-5049-3

  • 29

    FangQGShiSLiMZhangXLiuFYSunCF. Free Flap Reconstruction Versus non-Free Flap Reconstruction in Treating Elderly Patients With Advanced Oral Cancer. J Oral Maxillofac Surg Off J Am Assoc Oral Maxillofacial Surgeons (2014) 72(7):1420–4. doi: 10.1016/j.joms.2014.01.010

  • 30

    RühleAHaehlEKalckreuthTStoianRSpohnSKBSpraveTet al. Surviving Elderly Patients With Head-And-Neck Squamous Cell Carcinoma-What Is the Long-Term Quality of Life After Curative Radiotherapy? Cancers (Basel) (2021) 13(6):1275. doi: 10.3390/cancers13061275

  • 31

    BorggrevenPAAaronsonNKVerdonck-de LeeuwIMMullerMJHeiligersMLBreeRet al. Quality of Life After Surgical Treatment for Oral and Oropharyngeal Cancer: A Prospective Longitudinal Assessment of Patients Reconstructed by a Microvascular Flap. Oral Oncol (2007) 43(10):1034–42. doi: 10.1016/j.oraloncology.2006.11.017

  • 32

    HuZYFengXQFuMRYuRZhaoHL. Symptom Patterns, Physical Function and Quality of Life Among Head and Neck Cancer Patients Prior to and After Surgical Treatment: A Prospective Study. Eur J Oncol Nurs (2020) 46:101770. doi: 10.1016/j.ejon.2020.101770

  • 33

    RonisDLDuffySAFowlerKEKhanMJTerrellJE. Changes in Quality of Life Over 1 Year in Patients With Head and Neck Cancer. Arch Otolaryngol Head Neck Surg (2008) 134(3):241–8. doi: 10.1001/archoto.2007.43

  • 34

    SingerSDankerHGuntinas-LichiusOOekenJPabstFSchockJet al. Quality of Life Before and After Total Laryngectomy: Results of a Multicenter Prospective Cohort Study. Head Neck (2014) 36(3):359–68. doi: 10.1002/hed.23305

  • 35

    AllisonPJLockerDWood-DauphineeSBlackMFeineJS. Correlates of Health-Related Quality of Life in Upper Aerodigestive Tract Cancer Patients. Qual Life Res (1998) 7(8):713–22. doi: 10.1023/A:1008880816543

  • 36

    McDowellLCasswellGBresselMDrosdowskyARischinDColemanAet al. Symptom Burden, Quality of Life, Functioning and Emotional Distress in Survivors of Human Papillomavirus Associated Oropharyngeal Cancer: An Australian Cohort. Oral Oncol (2021) 122:105560. doi: 10.1016/j.oraloncology.2021.105560

  • 37

    MehannaHMMortonRP. Deterioration in Quality-of-Life of Late (10-Year) Survivors of Head and Neck Cancer. Clin Otolaryngol (2006) 31(3):204–11. doi: 10.1111/j.1749-4486.2006.01188.x

  • 38

    RamaekersBLJooreMAGruttersJPvan den EndePJongJHoubenRet al. The Impact of Late Treatment-Toxicity on Generic Health-Related Quality of Life in Head and Neck Cancer Patients After Radiotherapy. Oral Oncol (2011) 47(8):768–74. doi: 10.1016/j.oraloncology.2011.05.012

  • 39

    RogersLQRaoKMaloneJKandulaPRonenOMarkwellSJet al. Factors Associated With Quality of Life in Outpatients With Head and Neck Cancer 6 Months After Diagnosis. Head Neck (2009) 31(9):1207–14. doi: 10.1002/hed.21084

  • 40

    EuroQoL Group. EuroQol–a New Facility for the Measurement of Health-Related Quality of Life. Health Policy (1990) 16(3):199208. doi: 10.1016/0168-8510(90)90421-9

  • 41

    WareJJrKosinskiMKellerSD. A 12-Item Short-Form Health Survey: Construction of Scales and Preliminary Tests of Reliability and Validity. Med Care (1996) 34(3):220–33. doi: 10.1097/00005650-199603000-00003

  • 42

    BrazierJEHarperRJonesNMO'CathainAThomasKJUsherwoodTet al. Validating the SF-36 Health Survey Questionnaire: New Outcome Measure for Primary Care. Bmj (1992) 305(6846):160–4. doi: 10.1136/bmj.305.6846.160

  • 43

    AaronsonNKAhmedzaiSBergmanBBullingerMCullADuezNJet al. The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology. J Natl Cancer Inst (1993) 85(5):365–76. doi: 10.1093/jnci/85.5.365

  • 44

    BjordalKde GraeffAFayersPMHammerlidEvan PottelsbergheCCurranDet al. A 12 Country Field Study of the EORTC QLQ-C30 (Version 3.0) and the Head and Neck Cancer Specific Module (EORTC QLQ-H&N35) in Head and Neck Patients. Eur J Cancer (2000) 36(14):1796–807. doi: 10.1016/s0959-8049(00)00186-6

  • 45

    CellaDFTulskyDSGrayGSarafianBLinnEBonomiAet al. The Functional Assessment of Cancer Therapy Scale: Development and Validation of the General Measure. J Clin Oncol (1993) 11(3):570–9. doi: 10.1200/JCO.1993.11.3.570

  • 46

    MortonRPWitterickIJ. Rationale and Development of a Quality-of-Life Instrument for Head-and-Neck Cancer Patients. Am J Otolaryngol (1995) 16(5):284–93. doi: 10.1016/0196-0709(95)90055-1

  • 47

    BjordalKHammerlidEAhlner-ElmqvistMde GraeffABoysenMEvensenJFet al. Quality of Life in Head and Neck Cancer Patients: Validation of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-H&N35. J Clin Oncol (1999) 17(3):1008–19. doi: 10.1200/JCO.1999.17.3.1008

  • 48

    SingerSAmdalCDHammerlidETomaszewskaIMCastro SilvaJMehannaHet al. International Validation of the Revised European Organisation for Research and Treatment of Cancer Head and Neck Cancer Module, the EORTC QLQ-HN43: Phase Iv. Head Neck (2019) 41(6):1725–37. doi: 10.1002/hed.25609

  • 49

    ListMAD'AntonioLLCellaDFSistonAMumbyPHarafDet al. The Performance Status Scale for Head and Neck Cancer Patients and the Functional Assessment of Cancer Therapy-Head and Neck Scale. A Study of Utility and Validity. Cancer (1996) 77(11):2294–301. doi: 10.1002/(SICI)1097-0142(19960601)77:11<2294::AID-CNCR17>3.0.CO;2-S

  • 50

    TerrellJENanavatiKAEsclamadoRMBishopJKBradfordCRWolfGT. Head and Neck Cancer-Specific Quality of Life: Instrument Validation. Arch Otolaryngol Head Neck Surg (1997) 123(10):1125–32. doi: 10.1001/archotol.1997.01900100101014

  • 51

    FunkGFKarnellLHChristensenAJMoranPJRicksJ. Comprehensive Head and Neck Oncology Health Status Assessment. Head Neck (2003) 25(7):561–75. doi: 10.1002/hed.10245

  • 52

    HassanSJWeymullerEAJr. Assessment of Quality of Life in Head and Neck Cancer Patients. Head Neck (1993) 15(6):485–96. doi: 10.1002/hed.2880150603

  • 53

    RogersSNGwanneSLoweDHumphrisGYuehBWeymullerEAJr. The Addition of Mood and Anxiety Domains to the University of Washington Quality of Life Scale. Head Neck (2002) 24(6):521–9. doi: 10.1002/hed.10106

  • 54

    FitzsimmonsDGilbertJHowseFYoungTArrarrasJIBrédartAet al. A Systematic Review of the Use and Validation of Health-Related Quality of Life Instruments in Older Cancer Patients. Eur J Cancer (2009) 45(1):1932. doi: 10.1016/j.ejca.2008.07.036

  • 55

    JohnsonCFitzsimmonsDGilbertJArrarrasJIHammerlidEBredartAet al. Development of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Module for Older People With Cancer: The EORTC QLQ-Eld15. Eur J Cancer (2010) 46(12):2242–52. doi: 10.1016/j.ejca.2010.04.014

  • 56

    AmdurRJCheraBS. Misuse of Quality of Life Evaluation in Oncology Studies: Reification, Adaptation, and the U-Shaped Curve. Pract Radiat Oncol (2019) 9(4):191–2. doi: 10.1016/j.prro.2018.05.002

  • 57

    RingashJ. Re: Misuse of Quality of Life Evaluation in Oncology Studies. Pract Radiat Oncol (2019) 9(6):503. doi: 10.1016/j.prro.2019.07.016

  • 58

    McDowellLGoughKKingMCorryJRischinD. Patient-Reported Quality of Life and Symptom Burden Measures in Human Papillomavirus Associated Oropharyngeal Cancer - A Review of the Literature and PRO Methodology. Oral Oncol (2021) 118:105309. doi: 10.1016/j.oraloncology.2021.105309

  • 59

    SprangersMASchwartzCE. Integrating Response Shift Into Health-Related Quality of Life Research: A Theoretical Model. Soc Sci Med (1982) (1999) 48(11):1507–15. doi: 10.1016/S0277-9536(99)00045-3

  • 60

    BergMSilanderEBoveMJohanssonLNymanJHammerlidE. The Effect of Age on Health-Related Quality of Life for Head and Neck Cancer Patients Up to 1 Year After Curative Treatment. J Geriatr Oncol (2022) 13(1):60–6. doi: 10.1016/j.jgo.2021.06.009

  • 61

    CitakETulekZ. Longitudinal Quality of Life in Turkish Patients With Head and Neck Cancer Undergoing Radiotherapy. Support Care Cancer (2013) 21(8):2171–83. doi: 10.1007/s00520-013-1774-y

  • 62

    AokiTOtaYSasakiMSuzukiTUchiboriMNakanishiYet al. Quality of Life of Japanese Elderly Oral Cancer Patients During the Perioperative Period. Int J Oral Maxillofac Surg (2021) 50(9):1138–46. doi: 10.1016/j.ijom.2020.12.011

  • 63

    de GraeffAde LeeuwJRRosWJHordijkGJBlijhamGHWinnubstJA. Long-Term Quality of Life of Patients With Head and Neck Cancer. Laryngoscope (2000) 110(1):98106. doi: 10.1097/00005537-200001000-00018

  • 64

    de GraeffAde LeeuwJRRosWJHordijkGJBlijhamGHWinnubstJA. Pretreatment Factors Predicting Quality of Life After Treatment for Head and Neck Cancer. Head Neck (2000) 22(4):398407. doi: 10.1002/1097-0347(200007)22:4<398::AID-HED14>3.0.CO;2-V

  • 65

    DerksWDe LeeuwRWinnubstJHordijkGJ. Elderly Patients With Head and Neck Cancer: Physical, Social and Psychological Aspects After 1 Year. Acta Otolaryngol (2004) 124(4):509–14. doi: 10.1080/00016480310000656

  • 66

    DziegielewskiPTTeknosTNDurmusKOldMAgrawalAKakaralaKet al. Transoral Robotic Surgery for Oropharyngeal Cancer: Long-Term Quality of Life and Functional Outcomes. JAMA Otolaryngol– Head Neck Surg (2013) 139(11):1099–108. doi: 10.1001/jamaoto.2013.2747

  • 67

    FunkGFKarnellLHChristensenAJ. Long-Term Health-Related Quality of Life in Survivors of Head and Neck Cancer. Arch Otolaryngol Head Neck Surg (2012) 138(2):123–33. doi: 10.1001/archoto.2011.234

  • 68

    HammerlidESilanderEHörnestamLSullivanM. Health-Related Quality of Life Three Years After Diagnosis of Head and Neck Cancer - A Longitudinal Study. Head Neck (2001) 23(2):113–25. doi: 10.1002/1097-0347(200102)23:2<113::AID-HED1006>3.0.CO;2-W

  • 69

    BjordalKAhlner-ElmqvistMHammerlidEBoysenMEvensenJFBiorklundAet al. A Prospective Study of Quality of Life in Head and Neck Cancer Patients. Part II: Longitudinal Data. Laryngoscope (2001) 111(8):1440–52. doi: 10.1097/00005537-200108000-00022

  • 70

    ReeveBBCaiJZhangHWeisslerMCWisniewskiKGrossHet al. Factors That Impact Health-Related Quality of Life Over Time for Individuals With Head and Neck Cancer. Laryngoscope (2016) 126(12):2718–25. doi: 10.1002/lary.26073

  • 71

    RettigEMD'SouzaGThompsonCBKochWMEiseleDWFakhryC. Health-Related Quality of Life Before and After Head and Neck Squamous Cell Carcinoma: Analysis of the Surveillance, Epidemiology, and End Results-Medicare Health Outcomes Survey Linkage. Cancer (2016) 122(12):1861–70. doi: 10.1002/cncr.30005

  • 72

    van der SchroeffMPDerksWHordijkGJde LeeuwRJ. The Effect of Age on Survival and Quality of Life in Elderly Head and Neck Cancer Patients: A Long-Term Prospective Study. Eur Arch Otorhinolaryngol Off J Eur Fed Otorhinolaryngol Societies (2007) 264(4):415–22. doi: 10.1007/s00405-006-0203-y

  • 73

    BozecAPoissonnetGChamoreyECasanovaCVallicioniJDemardFet al. Free-Flap Head and Neck Reconstruction and Quality of Life: A 2-Year Prospective Study. Laryngoscope (2008) 118(5):874–80. doi: 10.1097/MLG.0b013e3181644abd

  • 74

    BozecADemezPGalJChamoreyELouisMYBlanchardDet al. Long-Term Quality of Life and Psycho-Social Outcomes After Oropharyngeal Cancer Surgery and Radial Forearm Free-Flap Reconstruction: A GETTEC Prospective Multicentric Study. Surg Oncol (2018) 27(1):2330. doi: 10.1016/j.suronc.2017.11.005

  • 75

    BozecASchultzPGalJChamoreyEChateauYDassonvilleOet al. Evolution and Predictive Factors of Quality of Life in Patients Undergoing Oncologic Surgery for Head and Neck Cancer: A Prospective Multicentric Study. Surg Oncol (2019) 28:236–42. doi: 10.1016/j.suronc.2019.01.012

  • 76

    DerksWDe LeeuwJRHordijkGJWinnubstJA. Elderly Patients With Head and Neck Cancer: Short-Term Effects of Surgical Treatment on Quality of Life. Clin Otolaryngol Allied Sci (2003) 28(5):399405. doi: 10.1046/j.1365-2273.2003.00718.x

  • 77

    DurmusKPatwaHSGokozanHNKucurCTeknosTNAgrawalAet al. Functional and Quality-of-Life Outcomes of Transoral Robotic Surgery for Carcinoma of Unknown Primary. Laryngoscope (2014) 124(9):2089–95. doi: 10.1002/lary.24705

  • 78

    SegnaEBolzoniARGiannìABBajABeltraminiGA. Impact of Reconstructive Microsurgery on Patients With Cancer of the Head and Neck: A Prospective Study of Quality of Life, Particularly in Older Patients. Br J Oral Maxillofac Surg (2018) 56(9):830–4. doi: 10.1016/j.bjoms.2018.09.003

  • 79

    YinXShanCWangJZhangH. Factors Associated With the Quality of Life for Hospitalized Patients With HPV-Associated Oropharyngeal Squamous Cell Carcinoma. Oral Oncol (2020) 103:104590. doi: 10.1016/j.oraloncology.2020.104590

  • 80

    YoshimuraRShibuyaHMiuraMWatanabeHAyukawaFHayashiKet al. Quality of Life of Oral Cancer Patients After Low-Dose-Rate Interstitial Brachytherapy. Int J Radiat Oncol Biol Phys (2009) 73(3):772–8. doi: 10.1016/j.ijrobp.2008.05.001

  • 81

    AlicikusZAAkmanFAtamanOUDagNOrcinEBakisBet al. Importance of Patient, Tumour and Treatment Related Factors on Quality of Life in Head and Neck Cancer Patients After Definitive Treatment. Eur Arch Otorhinolaryngol Off J Eur Fed Otorhinolaryngol Societies (2009) 266(9):1461–8. doi: 10.1007/s00405-008-0889-0

  • 82

    BaxiSSCullenGXiaoHAtoriaCLShermanEJHoAet al. Long-Term Quality of Life in Older Patients With HPV-Related Oropharyngeal Cancer. Head Neck (2018) 40(11):2321–8. doi: 10.1002/hed.25159

  • 83

    BonzaniniLILSolderaEBOrtigaraGBSchulzREAntoniazziRPArdenghiTMet al. Clinical and Sociodemographic Factors That Affect the Quality of Life of Survivors of Head and Neck Cancer. Support Care Cancer (2020) 28(4):1941–50. doi: 10.1007/s00520-019-05008-4

  • 84

    BozecAMajoufreCDe BoutrayMGalJChamoreyERousselLMet al. Oral and Oropharyngeal Cancer Surgery With Free-Flap Reconstruction in the Elderly: Factors Associated With Long-Term Quality of Life, Patient Needs and Concerns. A GETTEC cross-sectional study. Surg Oncol (2020) 35:81–8. doi: 10.1016/j.suronc.2020.08.014

  • 85

    DwivediRCSt RoseSChisholmEJYoussefiPHassanMSKhanASet al. Evaluation of Factors Affecting Post-Treatment Quality of Life in Oral and Oropharyngeal Cancer Patients Primarily Treated With Curative Surgery: An Exploratory Study. Eur Arch Otorhinolaryngol Off J Eur Fed Otorhinolaryngol Societies (2012) 269(2):591–9. doi: 10.1007/s00405-011-1621-z

  • 86

    Infante-CossioPTorres-CarranzaECayuelaAGutierrez-PerezJLGili-MinerM. Quality of Life in Patients With Oral and Oropharyngeal Cancer. Int J Oral Maxillofac Surg (2009) 38(3):250–5. doi: 10.1016/j.ijom.2008.12.001

  • 87

    LarawayDCLakshmiahRLoweDRoeBRogersSN. Quality of Life in Older People With Oral Cancer. Br J Oral Maxillofac Surg (2012) 50(8):715–20. doi: 10.1016/j.bjoms.2012.01.010

  • 88

    MorimataJOtomaruTMuraseMHaraguchiMSumitaYTaniguchiH. Investigation of Factor Affecting Health-Related Quality of Life in Head and Neck Cancer Patients. Gerodontology (2013) 30(3):194200. doi: 10.1111/j.1741-2358.2012.00662.x

  • 89

    PierreCSDassonvilleOChamoreyEPoissonnetGEttaicheMSantiniJet al. Long-Term Quality of Life and its Predictive Factors After Oncologic Surgery and Microvascular Reconstruction in Patients With Oral or Oropharyngeal Cancer. Eur Arch Otorhinolaryngol Off J Eur Fed Otorhinolaryngol Societies (2014) 271(4):801–7. doi: 10.1007/s00405-013-2592-z

  • 90

    PourelNPeiffertDLartigauEDesandesELuporsiEConroyT. Quality of Life in Long-Term Survivors of Oropharynx Carcinoma. Int J Radiat Oncol Biol Phys (2002) 54(3):742–51. doi: 10.1016/S0360-3016(02)02959-0

  • 91

    SilveiraAPGonçalvesJSequeiraTRibeiroCLopesCMonteiroEet al. Geriatric Oncology: Comparing Health Related Quality of Life in Head and Neck Cancer Patients. Head Neck Oncol (2011) 3(1):3. doi: 10.1186/1758-3284-3-3

  • 92

    VermaNTanXKnowlesMBernardSCheraB. Patient-Reported Outcomes for Dental Health, Shoulder-Neck Dysfunction, and Overall Quality of Life After Treatment With Radiation for Head and Neck Cancer. Laryngoscope Investig Otolaryngol (2019) 4(3):300–6. doi: 10.1002/lio2.262

  • 93

    WellsMSwartzmanSLangHCunninghamMTaylorLThomsonJet al. Predictors of Quality of Life in Head and Neck Cancer Survivors Up to 5 Years After End of Treatment: A Cross-Sectional Survey. Support Care Cancer (2016) 24(6):2463–72. doi: 10.1007/s00520-015-3045-6

  • 94

    WilliamsonJSIngramsDJonesH. Quality of Life After Treatment of Laryngeal Carcinoma: A Single Centre Cross-Sectional Study. Ann R Coll Surg Engl (2011) 93(8):591–5. doi: 10.1308/147870811X13137608455253

  • 95

    WoodardTDOplatekAPetruzzelliGJ. Life After Total Laryngectomy: A Measure of Long-Term Survival, Function, and Quality of Life. Arch Otolaryngol Head Neck Surg (2007) 133(6):526–32. doi: 10.1001/archotol.133.6.526

  • 96

    OsobaDRodriguesGMylesJZeeBPaterJ. Interpreting the Significance of Changes in Health-Related Quality-of-Life Scores. J Clin Oncol (1998) 16(1):139–44. doi: 10.1200/JCO.1998.16.1.139

  • 97

    CocksKKingMTVelikovaGMartyn St-JamesMFayersPMBrownJM. Evidence-Based Guidelines for Determination of Sample Size and Interpretation of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30. J Clin Oncol (2011) 29(1):8996. doi: 10.1200/JCO.2010.28.0107

  • 98

    RingashJBezjakAO'SullivanBRedelmeierDA. Interpreting Differences in Quality of Life: The FACT-H&N in Laryngeal Cancer Patients. Qual Life Res (2004) 13(4):725–33. doi: 10.1023/B:QURE.0000021703.47079.46

  • 99

    HammerlidEBjordalKAhlner-ElmqvistMBoysenMEvensenJFBiörklundAet al. A Prospective Study of Quality of Life in Head and Neck Cancer Patients. Part I: At Diagnosis. Laryngoscope (2001) 111(4 Pt 1):669–80. doi: 10.1097/00005537-200104000-00021

  • 100

    HammermüllerCHinzADietzAWichmannGPirlichMBergerTet al. Depression, Anxiety, Fatigue, and Quality of Life in a Large Sample of Patients Suffering From Head and Neck Cancer in Comparison With the General Population. BMC Cancer (2021) 21(1):94. doi: 10.1186/s12885-020-07773-6

  • 101

    HollandJCAndersenBBreitbartWSCompasBDudleyMMFleishmanSet al. Distress Management. J Natl Compr Canc Netw (2010) 8(4):448–85. doi: 10.6004/jnccn.2010.0034

  • 102

    YesavageJABrinkTLRoseTLLumOHuangVAdeyMet al. Development and Validation of a Geriatric Depression Screening Scale: A Preliminary Report. J Psychiatr Res (1982) 17(1):3749. doi: 10.1016/0022-3956(82)90033-4

  • 103

    ZigmondASSnaithRP. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand (1983) 67(6):361–70. doi: 10.1111/j.1600-0447.1983.tb09716.x

  • 104

    PilkonisPAChoiSWReiseSPStoverAMRileyWTCellaDet al. Item Banks for Measuring Emotional Distress From the Patient-Reported Outcomes Measurement Information System (PROMIS(R)): Depression, Anxiety, and Anger. Assessment (2011) 18(3):263–83. doi: 10.1177/1073191111411667

  • 105

    Beck ATSRBrownGK. BDI®-II Manual. San Antonio, TX, USA: The Psychological Corporation (1996).

  • 106

    RadloffLS. The CES-D Scale:A Self-Report Depression Scale for Research in the General Population. Appl psychol Meas (1977) 1(3):385401. doi: 10.1177/014662167700100306

  • 107

    RamanaiahNVFranzenMSchillT. A Psychometric Study of the State-Trait Anxiety Inventory. J Pers Assess (1983) 47(5):531–5. doi: 10.1207/s15327752jpa4705_14

  • 108

    HamiltonM. Development of a Rating Scale for Primary Depressive Illness. Br J Soc Clin Psychol (1967) 6(4):278–96. doi: 10.1111/j.2044-8260.1967.tb00530.x

  • 109

    SheehanDVLecrubierYSheehanKHAmorimPJanavsJWeillerEet al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): The Development and Validation of a Structured Diagnostic Psychiatric Interview for DSM-IV and ICD-10. J Clin Psychiatry (1998) 59 Suppl 20:2233;quiz 4-57.

  • 110

    LenderkingWRHuMTennenHCappelleriJCPetrieCDRushAJ. Daily Process Methodology for Measuring Earlier Antidepressant Response. Contemp Clin Trials (2008) 29(6):867–77. doi: 10.1016/j.cct.2008.05.012

  • 111

    CarverCSScheierMFWeintraubJK. Assessing Coping Strategies: A Theoretically Based Approach. J Pers Soc Psychol (1989) 56(2):267–83. doi: 10.1037/0022-3514.56.2.267

  • 112

    KroenkeKSpitzerRLWilliamsJB. The PHQ-9: Validity of a Brief Depression Severity Measure. J Gen Intern Med (2001) 16(9):606–13. doi: 10.1046/j.1525-1497.2001.016009606.x

  • 113

    BroadbentEPetrieKJMainJWeinmanJ. The Brief Illness Perception Questionnaire. J Psychosom Res (2006) 60(6):631–7. doi: 10.1016/j.jpsychores.2005.10.020

  • 114

    KertzSBigda-PeytonJBjorgvinssonT. Validity of the Generalized Anxiety Disorder-7 Scale in an Acute Psychiatric Sample. Clin Psychol Psychother (2013) 20(5):456–64. doi: 10.1002/cpp.1802

  • 115

    RothAJKornblithABBatel-CopelLPeabodyEScherHIHollandJC. Rapid Screening for Psychologic Distress in Men With Prostate Carcinoma: A Pilot Study. Cancer (1998) 82(10):1904–8. doi: 10.1002/(SICI)1097-0142(19980515)82:10<1904::AID-CNCR13>3.0.CO;2-X

  • 116

    WatsonMGreerSYoungJInayatQBurgessCRobertsonB. Development of a Questionnaire Measure of Adjustment to Cancer: The MAC Scale. psychol Med (1988) 18(1):203–9. doi: 10.1017/S0033291700002026

  • 117

    ThomasBCMohanVNThomasIPandeyM. Development of a Distress Inventory for Cancer: Preliminary Results. J Postgrad Med (2002) 48(1):1620.

  • 118

    RogersSNEl-SheikhaJLoweD. The Development of a Patients Concerns Inventory (PCI) to Help Reveal Patients Concerns in the Head and Neck Clinic. Oral Oncol (2009) 45(7):555–61. doi: 10.1016/j.oraloncology.2008.09.004

  • 119

    BadrHGuptaVSikoraAPosnerM. Psychological Distress in Patients and Caregivers Over the Course of Radiotherapy for Head and Neck Cancer. Oral Oncol (2014) 50(10):1005–11. doi: 10.1016/j.oraloncology.2014.07.003

  • 120

    KroenkeCHKubzanskyLDSchernhammerESHolmesMDKawachiI. Social Networks, Social Support, and Survival After Breast Cancer Diagnosis. J Clin Oncol (2006) 24(7):1105–11. doi: 10.1200/JCO.2005.04.2846

  • 121

    CailletPCanoui-PoitrineFVouriotJBerleMReinaldNKrypciakSet al. Comprehensive Geriatric Assessment in the Decision-Making Process in Elderly Patients With Cancer: ELCAPA Study. J Clin Oncol (2011) 29(27):3636–42. doi: 10.1200/JCO.2010.31.0664

  • 122

    SenchakJJFangCYBaumanJR. Interventions to Improve Quality of Life (QOL) and/or Mood in Patients With Head and Neck Cancer (HNC): A Review of the Evidence. Cancers Head Neck (2019) 4:2. doi: 10.1186/s41199-019-0041-4

  • 123

    CashEDuckCRBrinkmanCRebholzWAlbertCWorthenMet al. Depressive Symptoms and Actigraphy-Measured Circadian Disruption Predict Head and Neck Cancer Survival. Psychooncology (2018) 27(10):2500–7. doi: 10.1002/pon.4862

  • 124

    ChenAMJennelleRLGradyVTovarABowenKSimoninPet al. Prospective Study of Psychosocial Distress Among Patients Undergoing Radiotherapy for Head and Neck Cancer. Int J Radiat Oncol Biol Phys (2009) 73(1):187–93. doi: 10.1016/j.ijrobp.2008.04.010

  • 125

    D'SouzaVBlouinEZeitouniAMullerKAllisonPJ. An Investigation of the Effect of Tailored Information on Symptoms of Anxiety and Depression in Head and Neck Cancer Patients. Oral Oncol (2013) 49(5):431–7. doi: 10.1016/j.oraloncology.2012.12.001

  • 126

    GhazaliNRoeBLoweDTandonSJonesTBrownJet al. Screening for Distress Using the Distress Thermometer and the University of Washington Quality of Life in Post-Treatment Head and Neck Cancer Survivors. Eur Arch Otorhinolaryngol Off J Eur Fed Otorhinolaryngol Societies (2017) 274(5):2253–60. doi: 10.1007/s00405-017-4474-2

  • 127

    HammerlidEAhlner-ElmqvistMBjordalKBiorklundAEvensenJBoysenMet al. A Prospective Multicentre Study in Sweden and Norway of Mental Distress and Psychiatric Morbidity in Head and Neck Cancer Patients. Br J Cancer (1999) 80(5-6):766–74. doi: 10.1038/sj.bjc.6690420

  • 128

    HorneyDJSmithHEMcGurkMWeinmanJHeroldJAltmanKet al. Associations Between Quality of Life, Coping Styles, Optimism, and Anxiety and Depression in Pretreatment Patients With Head and Neck Cancer. Head Neck (2011) 33(1):6571. doi: 10.1002/hed.21407

  • 129

    HowrenMBChristensenAJKarnellLHFunkGF. Health-Related Quality of Life in Head and Neck Cancer Survivors: Impact of Pretreatment Depressive Symptoms. Health Psychol (2010) 29(1):6571. doi: 10.1037/a0017788

  • 130

    HumphrisGMRogersSN. The Association of Cigarette Smoking and Anxiety, Depression and Fears of Recurrence in Patients Following Treatment of Oral and Oropharyngeal Malignancy. Eur J Cancer Care (Engl) (2004) 13(4):328–35. doi: 10.1111/j.1365-2354.2004.00479.x

  • 131

    IchikuraKYamashitaASugimotoTKishimotoSMatsushimaE. Persistence of Psychological Distress and Correlated Factors Among Patients With Head and Neck Cancer. Palliat Support Care (2016) 14(1):4251. doi: 10.1017/S1478951515000711

  • 132

    KanatasAGhazaliNLoweDRogersSN. The Identification of Mood and Anxiety Concerns Using the Patients Concerns Inventory Following Head and Neck Cancer. Int J Oral Maxillofac Surg (2012) 41(4):429–36. doi: 10.1016/j.ijom.2011.12.021

  • 133

    KumarKKumarSMehrotraDTiwariSCKumarVKhandpurSet al. Prospective Evaluation of Psychological Burden in Patients With Oral Cancer. Br J Oral Maxillofac Surg (2018) 56(10):918–24. doi: 10.1016/j.bjoms.2018.09.004

  • 134

    NeilsonKPollardABoonzaierACorryJCastleDSmithDet al. A Longitudinal Study of Distress (Depression and Anxiety) Up to 18 Months After Radiotherapy for Head and Neck Cancer. Psychooncology (2013) 22(8):1843–8. doi: 10.1002/pon.3228

  • 135

    JosephLARoutledgeJABurnsMPSwindellRSykesAJSlevinNJet al. Value of the Hospital Anxiety and Depression Scale in the Follow Up of Head and Neck Cancer Patients. J Laryngol Otol (2013) 127(3):285–94. doi: 10.1017/S0022215113000078

  • 136

    TangPLWangCHungMFLinHS. Assessment of Symptom Distress in Cancer Patients Before and After Radiotherapy. Cancer Nurs (2011) 34(1):7884. doi: 10.1097/NCC.0b013e3181f04ac8

  • 137

    van BeekFEJansenFMakLLissenberg-WitteBIButerJVergeerMRet al. The Course of Symptoms of Anxiety and Depression From Time of Diagnosis Up to 2 Years Follow-Up in Head and Neck Cancer Patients Treated With Primary (Chemo)Radiation. Oral Oncol (2020) 102:104576. doi: 10.1016/j.oraloncology.2020.104576

  • 138

    WangYLuWShenX. Assessment of Preoperative Psychologic Distress in Laryngeal Cancer Patients. Acta Otolaryngol (2019) 139(2):184–6. doi: 10.1080/00016489.2018.1523555

  • 139

    McCaffreyJCWeitznerMKamboukasDHaselhuhnGLamondeLBooth-JonesM. Alcoholism, Depression, and Abnormal Cognition in Head and Neck Cancer: A Pilot Study. Otolaryngol Head Neck Surg (2007) 136(1):92–7. doi: 10.1016/j.otohns.2006.06.1275

  • 140

    WangCChenJSuLHuaYYeJSongXet al. The Psychological Status in Patients With Nasopharyngeal Carcinoma During Radiotherapy. Eur Arch Otorhinolaryngol (2022) 279(2):1035–42. doi: 10.1007/s00405-021-06892-5

  • 141

    AstrupGLRustoenTMiaskowskiCPaulSMBjordalK. A Longitudinal Study of Depressive Symptoms in Patients With Head and Neck Cancer Undergoing Radiotherapy. Cancer Nurs (2015) 38(6):436–46. doi: 10.1097/NCC.0000000000000225

  • 142

    BjordalKKaasaS. Psychological Distress in Head and Neck Cancer Patients 7-11 Years After Curative Treatment. Br J Cancer (1995) 71(3):592–7. doi: 10.1038/bjc.1995.115

  • 143

    ChenAMHsuSFelixCGarstJYoshizakiT. Effect of Psychosocial Distress on Outcome for Head and Neck Cancer Patients Undergoing Radiation. Laryngoscope (2018) 128(3):641–5. doi: 10.1002/lary.26751

  • 144

    de LeeuwJRde GraeffARosWJBlijhamGHHordijkGJWinnubstJA. Prediction of Depressive Symptomatology After Treatment of Head and Neck Cancer: The Influence of Pre-Treatment Physical and Depressive Symptoms, Coping, and Social Support. Head Neck (2000) 22(8):799807. doi: 10.1002/1097-0347(200012)22:8<799::AID-HED9>3.0.CO;2-E

  • 145

    DengYTZhongWNJiangY. Measurement of Distress and its Alteration During Treatment in Patients With Nasopharyngeal Carcinoma. Head Neck (2014) 36(8):1077–86. doi: 10.1002/hed.23412

  • 146

    DerksWLeeuwJRHordijkGJWinnubstJA. Differences in Coping Style and Locus of Control Between Older and Younger Patients With Head and Neck Cancer. Clin Otolaryngol (2005) 30(2):186–92. doi: 10.1111/j.1365-2273.2004.00938.x

  • 147

    HenryMFuehrmannFHierMZeitouniAKostKRichardsonKet al. Contextual and Historical Factors for Increased Levels of Anxiety and Depression in Patients With Head and Neck Cancer: A Prospective Longitudinal Study. Head Neck (2019) 41(8):2538–48. doi: 10.1002/hed.25725

  • 148

    KimSARohJLLeeSALeeSWKimSBChoiSHet al. Pretreatment Depression as a Prognostic Indicator of Survival and Nutritional Status in Patients With Head and Neck Cancer. Cancer (2016) 122(1):131–40. doi: 10.1002/cncr.29693

  • 149

    KobayashiMSugimotoTMatsudaAMatsushimaEKishimotoS. Association Between Self-Esteem and Depression Among Patients With Head and Neck Cancer: A Pilot Study. Head Neck (2008) 30(10):1303–9. doi: 10.1002/hed.20868

  • 150

    KugayaAAkechiTOkuyamaTNakanoTMikamiIOkamuraHet al. Prevalence, Predictive Factors, and Screening for Psychologic Distress in Patients With Newly Diagnosed Head and Neck Cancer. Cancer (2000) 88(12):2817–23. doi: 10.1002/1097-0142(20000615)88:12<2817::AID-CNCR22>3.0.CO;2-N

  • 151

    KunzVWichmannGLehmann-LaueAMehnert-TheuerkaufADietzAWiegandS. Screening for Distress, Related Problems and Perceived Need for Psycho-Oncological Support in Head and Neck Squamous Cell Carcinoma (HNSCC) Patients: A Retrospective Cohort Study. BMC Cancer (2021) 21(1):478. doi: 10.1186/s12885-021-08236-2

  • 152

    NeilsonKAPollardACBoonzaierAMCorryJCastleDJMeadKRet al. Psychological Distress (Depression and Anxiety) in People With Head and Neck Cancers. Med J Aust (2010) 193(S5):S48–51. doi: 10.5694/j.1326-5377.2010.tb03928.x

  • 153

    PanwarARiekeKBurkeWJSaylesHLydiattWMPrevention of Depression in Patients Being Treated for Het al. Identification of Baseline Characteristics Associated With Development of Depression Among Patients With Head and Neck Cancer: A Secondary Analysis of a Randomized Clinical Trial. JAMA Otolaryngol– Head Neck Surg (2018) 144(11):1004–10. doi: 10.1001/jamaoto.2018.2228

  • 154

    SchellJTPetermann-MeyerAKloss-BrandstatterABartellaAKKamalMHolzleFet al. Distress Thermometer for Preoperative Screening of Patients With Oral Squamous Cell Carcinoma. J Craniomaxillofac Surg (2018) 46(7):1111–6. doi: 10.1016/j.jcms.2018.04.022

  • 155

    SpeksnijderCMLankhorstPJMde BreeRde HaanAFJKooleRMerkxMAW. Depression and Related Factors After Oral Oncological Treatment: A 5-Year Prospective Cohort Study. Support Care Cancer (2021) 29(6):2907–16. doi: 10.1007/s00520-020-05795-1

  • 156

    Verdonck-de LeeuwIMde BreeRKeizerALHouffelaarTCuijpersPvan der LindenMHet al. Computerized Prospective Screening for High Levels of Emotional Distress in Head and Neck Cancer Patients and Referral Rate to Psychosocial Care. Oral Oncol (2009) 45(10):e129–33. doi: 10.1016/j.oraloncology.2009.01.012

  • 157

    ThomasMLKaufmannCNPalmerBWDeppCAMartinASGloriosoDKet al. Paradoxical Trend for Improvement in Mental Health With Aging: A Community-Based Study of 1,546 Adults Aged 21-100 Years. J Clin Psychiatry (2016) 77(8):e1019–25. doi: 10.4088/JCP.16m10671

  • 158

    MirosevicSThewesBvan HerpenCKaandersJMerkxTHumphrisGet al. Prevalence and Clinical and Psychological Correlates of High Fear of Cancer Recurrence in Patients Newly Diagnosed With Head and Neck Cancer. Head Neck (2019) 41(9):3187–200. doi: 10.1002/hed.25812

  • 159

    CasswellGGoughKDrosdowskyABresselMColemanAShresthaSet al. Fear of Cancer Recurrence in Survivors of Human Papillomavirus-Associated Oropharyngeal Carcinoma. Int J Radiat Oncol Biol Phys (2021) 111(4):890–9. doi: 10.1016/j.ijrobp.2021.07.006

  • 160

    RogersSNMonssenCHumphrisGMLoweDKanatasA. Which Head and Neck Cancer Patients Are Most at Risk of High Levels of Fear of Cancer Recurrence. Front Psychol (2021) 12:671366. doi: 10.3389/fpsyg.2021.671366

  • 161

    GhazaliNCadwalladerELoweDHumphrisGOzakinciGRogersSN. Fear of Recurrence Among Head and Neck Cancer Survivors: Longitudinal Trends. Psychooncology (2013) 22(4):807–13. doi: 10.1002/pon.3069

  • 162

    KanatasAHumphrisGLoweDRogersSN. Further Analysis of the Emotional Consequences of Head and Neck Cancer as Reflected by the Patients' Concerns Inventory. Br J Oral Maxillofac Surg (2015) 53(8):711–8. doi: 10.1016/j.bjoms.2015.02.026

  • 163

    RogersSNCrossBTalwarCLoweDHumphrisG. A Single-Item Screening Question for Fear of Recurrence in Head and Neck Cancer. Eur Arch Otorhinolaryngol Off J Eur Fed Otorhinolaryngol Societies (2016) 273(5):1235–42. doi: 10.1007/s00405-015-3585-x

  • 164

    RogersSNAudisioRALoweD. Do the Elderly Raise Different Issues When Using the Patient Concerns Inventory in Routine Head and Neck Cancer Follow-Up Clinics? Eur J Cancer Care (Engl) (2015) 24(2):189–97. doi: 10.1111/ecc.12289

  • 165

    RylandsJLoweDRogersSN. Influence of Deprivation on Health-Related Quality of Life of Patients With Cancer of the Head and Neck in Merseyside and Cheshire. Br J Oral Maxillofac Surg (2016) 54(6):669–76. doi: 10.1016/j.bjoms.2016.03.030

  • 166

    RogersSNScottBLoweDOzakinciGHumphrisGM. Fear of Recurrence Following Head and Neck Cancer in the Outpatient Clinic. Eur Arch Otorhinolaryngol Off J Eur Fed Otorhinolaryngol Societies (2010) 267(12):1943–9. doi: 10.1007/s00405-010-1307-y

  • 167

    LlewellynCDWeinmanJMcGurkMHumphrisG. Can We Predict Which Head and Neck Cancer Survivors Develop Fears of Recurrence? J Psychosomatic Res (2008) 65(6):525–32. doi: 10.1016/j.jpsychores.2008.03.014

  • 168

    Van LiewJRChristensenAJHowrenMBHynds KarnellLFunkGF. Fear of Recurrence Impacts Health-Related Quality of Life and Continued Tobacco Use in Head and Neck Cancer Survivors. Health Psychol Off J Division Health Psychology Am psychol Assoc (2014) 33(4):373–81. doi: 10.1037/a0032680

  • 169

    SimardSSavardJ. Fear of Cancer Recurrence Inventory: Development and Initial Validation of a Multidimensional Measure of Fear of Cancer Recurrence. Support Care Cancer (2009) 17(3):241–51. doi: 10.1007/s00520-008-0444-y

  • 170

    SimardSSavardJ. Screening and Comorbidity of Clinical Levels of Fear of Cancer Recurrence. J Cancer Surviv (2015) 9(3):481–91. doi: 10.1007/s11764-015-0424-4

  • 171

    SimardSThewesBHumphrisGDixonMHaydenCMireskandariSet al. Fear of Cancer Recurrence in Adult Cancer Survivors: A Systematic Review of Quantitative Studies. J Cancer Surviv (2013) 7(3):300–22. doi: 10.1007/s11764-013-0272-z

  • 172

    ChenCCaoJWangLZhangRLiHPengJ. Body Image and its Associated Factors Among Chinese Head and Neck Cancer Patients Undergoing Surgical Treatment: A Cross-Sectional Survey. Support Care Cancer (2020) 28(3):1233–9. doi: 10.1007/s00520-019-04940-9

  • 173

    ClarkeSANewellRThompsonAHarcourtDLindenmeyerA. Appearance Concerns and Psychosocial Adjustment Following Head and Neck Cancer: A Cross-Sectional Study and Nine-Month Follow-Up. Psychol Health Med (2014) 19(5):505–18. doi: 10.1080/13548506.2013.855319

  • 174

    ChangDCChenAWLoYSChuangYCChenMK. Factors Associated With Suicidal Ideation Risk in Head and Neck Cancer: A Longitudinal Study. Laryngoscope (2019) 129(11):2491–5. doi: 10.1002/lary.27843

  • 175

    ZebolskyALOchoaEBadranKWHeatonCParkASethRet al. Appearance-Related Distress and Social Functioning After Head and Neck Microvascular Reconstruction. Laryngoscope (2021) 131(7):E2204–11. doi: 10.1002/lary.29548

  • 176

    CramerJDJohnsonJTNilsenML. Pain in Head and Neck Cancer Survivors: Prevalence, Predictors, and Quality-Of-Life Impact. Otolaryngol Head Neck Surg (2018) 159(5):853–8. doi: 10.1177/0194599818783964

  • 177

    MoyeJJuneAMartinLAGosianJHermanLINaikAD. Pain is Prevalent and Persisting in Cancer Survivors: Differential Factors Across Age Groups. J Geriatr Oncol (2014) 5(2):190–6. doi: 10.1016/j.jgo.2013.12.006

  • 178

    HassaneinKAMusgroveBTBradburyE. Functional Status of Patients With Oral Cancer and its Relation to Style of Coping, Social Support and Psychological Status. Br J Oral Maxillofac Surg (2001) 39(5):340–5. doi: 10.1054/bjom.2001.0652

  • 179

    HickokJTRoscoeJAMorrowGRMustianKOkunieffPBoleCW. Frequency, Severity, Clinical Course, and Correlates of Fatigue in 372 Patients During 5 Weeks of Radiotherapy for Cancer. Cancer (2005) 104(8):1772–8. doi: 10.1002/cncr.21364

  • 180

    RogersLQCourneyaKSRobbinsKTRaoKMaloneJSeizAet al. Factors Associated With Fatigue, Sleep, and Cognitive Function Among Patients With Head and Neck Cancer. Head Neck (2008) 30(10):1310–7. doi: 10.1002/hed.20873

  • 181

    SantosoAMMJansenFLissenberg-WitteBIBaatenburg de JongRJLangendijkJALeemansCRet al. Poor Sleep Quality Among Newly Diagnosed Head and Neck Cancer Patients: Prevalence and Associated Factors. Support Care Cancer (2021) 29(2):1035–45. doi: 10.1007/s00520-020-05577-9

  • 182

    HoltmaatKvan der SpekNCuijpersPLeemansCRVerdonck-de LeeuwIM. Posttraumatic Growth Among Head and Neck Cancer Survivors With Psychological Distress. Psychooncology (2017) 26(1):96101. doi: 10.1002/pon.4106

  • 183

    KangasMHenryJLBryantRA. Predictors of Posttraumatic Stress Disorder Following Cancer. Health Psychol (2005) 24(6):579–85. doi: 10.1037/0278-6133.24.6.579

  • 184

    MoschopoulouEHutchisonIBhuiKKorszunA. Post-Traumatic Stress in Head and Neck Cancer Survivors and Their Partners. Support Care Cancer (2018) 26(9):3003–11. doi: 10.1007/s00520-018-4146-9

  • 185

    PoslusznyDMDougallALJohnsonJTArgirisAFerrisRLBaumAet al. Posttraumatic Stress Disorder Symptoms in Newly Diagnosed Patients With Head and Neck Cancer and Their Partners. Head Neck (2015) 37(9):1282–9. doi: 10.1002/hed.23760

  • 186

    RichardsonAEMortonRPBroadbentE. Coping Strategies Predict Post-Traumatic Stress in Patients With Head and Neck Cancer. Eur Arch Otorhinolaryngol (2016) 273(10):3385–91. doi: 10.1007/s00405-016-3960-2

  • 187

    AarstadAKBeislandEAarstadHJ. Personality, Choice of Coping and T Stage Predict Level of Distress in Head and Neck Cancer Patients During Follow-Up. Eur Arch Otorhinolaryngol (2012) 269(9):2121–8. doi: 10.1007/s00405-011-1884-4

  • 188

    AarstadAKBeislandEOsthusAAAarstadHJ. Distress, Quality of Life, Neuroticism and Psychological Coping are Related in Head and Neck Cancer Patients During Follow-Up. Acta Oncol (2011) 50(3):390–8. doi: 10.3109/0284186X.2010.504227

  • 189

    IchikuraKYamashitaASugimotoTKishimotoSMatsushimaE. Patterns of Stress Coping and Depression Among Patients With Head and Neck Cancer: A Japanese Cross-Sectional Study. Psychooncology (2018) 27(2):556–62. doi: 10.1002/pon.4549

  • 190

    Verdonck-de LeeuwIMEerensteinSEvan der LindenMHKuikDJde BreeRLeemansCR. Distress in Spouses and Patients After Treatment for Head and Neck Cancer. Laryngoscope (2007) 117(2):238–41. doi: 10.1097/01.mlg.0000250169.10241.58

  • 191

    ZaorskyNGZhangYTuanquinLBluethmannSMParkHSChinchilliVM. Suicide Among Cancer Patients. Nat Commun (2019) 10(1):207. doi: 10.1038/s41467-018-08170-1

  • 192

    AnguianoLMayerDKPivenMLRosensteinD. A Literature Review of Suicide in Cancer Patients. Cancer Nurs (2012) 35(4):E14–26. doi: 10.1097/NCC.0b013e31822fc76c

  • 193

    ChoiJWParkEC. Suicide Risk After Cancer Diagnosis Among Older Adults: A Nationwide Retrospective Cohort Study. J Geriatr Oncol (2020) 11(5):814–9. doi: 10.1016/j.jgo.2019.11.006

  • 194

    Osazuwa-PetersNSimpsonMCZhaoLBoakyeEAOlomukoroSIDeshieldsTet al. Suicide Risk Among Cancer Survivors: Head and Neck Versus Other Cancers. Cancer (2018) 124(20):4072–9. doi: 10.1002/cncr.31675

  • 195

    NoelCWEskanderASutradharRMaharAVigodSNIsenberg-GrzedaEet al. Incidence of and Factors Associated With Nonfatal Self-Injury After a Cancer Diagnosis in Ontario, Canada. JAMA Netw Open (2021) 4(9):e2126822. doi: 10.1001/jamanetworkopen.2021.26822

  • 196

    FangFFallKMittlemanMASparénPYeWAdamiHOet al. Suicide and Cardiovascular Death After a Cancer Diagnosis. N Engl J Med (2012) 366(14):1310–8. doi: 10.1056/NEJMoa1110307

  • 197

    KlaassenZWallisCJDChandrasekarTGoldbergHSayyidRKWilliamsSBet al. Cancer Diagnosis and Risk of Suicide After Accounting for Prediagnosis Psychiatric Care: A Matched-Cohort Study of Patients With Incident Solid-Organ Malignancies. Cancer (2019) 125(16):2886–95. doi: 10.1002/cncr.32146

  • 198

    ShunmugasundaramCRutherfordCButowPNSundaresanPDhillonHM. Content Comparison of Unmet Needs Self-Report Measures Used in Patients With Head and Neck Cancer: A Systematic Review. Psychooncology (2019) 28(12):2295–306. doi: 10.1002/pon.5257

  • 199

    GiulianiMMcQuestionMJonesJPapadakosJLeLWAlkazazNet al. Prevalence and Nature of Survivorship Needs in Patients With Head and Neck Cancer. Head Neck (2016) 38(7):1097–103. doi: 10.1002/hed.24411

  • 200

    HenryMHabibLAMorrisonMYangJWLiXJLinSet al. Head and Neck Cancer Patients Want Us to Support Them Psychologically in the Posttreatment Period: Survey Results. Palliat Support Care (2014) 12(6):481–93. doi: 10.1017/S1478951513000771

  • 201

    HenryMAliasACherbaMWoronkoCRosbergerZHierMet al. Immediate Post-Treatment Supportive Care Needs of Patients Newly Diagnosed With Head and Neck Cancer. Support Care Cancer (2020) 28(11):5557–67. doi: 10.1007/s00520-020-05368-2

  • 202

    WellsMCunninghamMLangHSwartzmanSPhilpJTaylorLet al. Distress, Concerns and Unmet Needs in Survivors of Head and Neck Cancer: A Cross-Sectional Survey. Eur J Cancer Care (2015) 24(5):748–60. doi: 10.1111/ecc.12370

  • 203

    GhazaliNRoeBLoweDRogersSN. Patients Concerns Inventory Highlights Perceived Needs and Concerns in Head and Neck Cancer Survivors and its Impact on Health-Related Quality of Life. Br J Oral Maxillofac Surg (2015) 53(4):371–9. doi: 10.1016/j.bjoms.2015.01.022

  • 204

    O'BrienKMTimmonsAButowPGooberman-HillRO'SullivanEBalfeMet al. Associations Between Neighbourhood Support and Financial Burden With Unmet Needs of Head and Neck Cancer Survivors. Oral Oncol (2017) 65:5764. doi: 10.1016/j.oraloncology.2016.12.019

  • 205

    ManneSHudsonSVBaredesSStroupAVirtueSMPaddockLet al. Survivorship Care Experiences, Information, and Support Needs of Patients With Oral and Oropharyngeal Cancer. Head Neck (2016) 38 Suppl 1(Suppl 1):E1935–46. doi: 10.1002/hed.24351

  • 206

    ChenSCLiaoCTLinCCChangJTLaiYH. Distress and Care Needs in Newly Diagnosed Oral Cavity Cancer Patients Receiving Surgery. Oral Oncol (2009) 45(9):815–20. doi: 10.1016/j.oraloncology.2009.01.001

  • 207

    LeeMSNelsonAMThompsonLMDonovanKA. Supportive Care Needs of Oral Cancer Survivors: Prevalence and Correlates. Oral Oncol (2016) 53:8590. doi: 10.1016/j.oraloncology.2015.11.007

  • 208

    GhazaliNRoeBLoweDRogersSN. Uncovering Patients′ Concerns in Routine Head and Neck Oncology Follow Up Clinics: An Exploratory Study. Br J Oral Maxillofacial Surg (2013) 51(4):294300. doi: 10.1016/j.bjoms.2012.08.002

  • 209

    RubensteinLZStuckAESiuALWielandD. Impacts of Geriatric Evaluation and Management Programs on Defined Outcomes: Overview of the Evidence. J Am Geriatrics Soc (1991) 39(9 Pt 2):8S16S; discussion 7S-8S. doi: 10.1111/j.1532-5415.1991.tb05927.x

  • 210

    WildiersHHeerenPPutsMTopinkovaEJanssen-HeijnenMLExtermannMet al. International Society of Geriatric Oncology Consensus on Geriatric Assessment in Older Patients With Cancer. J Clin Oncol (2014) 32(24):2595–603. doi: 10.1200/JCO.2013.54.8347

  • 211

    NeveMJamesonMBGovenderSHartopeanuC. Impact of Geriatric Assessment on the Management of Older Adults With Head and Neck Cancer: A Pilot Study. J Geriatr Oncol (2016) 7(6):457–62. doi: 10.1016/j.jgo.2016.05.006

  • 212

    RaabGRestifoDMcBrideSMWongRJLeeNYShahrokniAet al. Outcomes Following Head and Neck Cancer Surgery Among Older Adults as Determined by an Electronic Geriatric Assessment. J Geriatr Oncol (2021) S1879-4068(21):00242–3. doi: 10.1016/j.jgo.2021.10.010

  • 213

    BrasLde VriesJFestenSSteenbakkersRLangendijkJAWitjesMJHet al. Frailty and Restrictions in Geriatric Domains are Associated With Surgical Complications But Not With Radiation-Induced Acute Toxicity in Head and Neck Cancer Patients: A Prospective Study. Oral Oncol (2021) 118:105329. doi: 10.1016/j.oraloncology.2021.105329

  • 214

    VanderWaldeNADealAMComitzEStraversLMussHReeveBBet al. Geriatric Assessment as a Predictor of Tolerance, Quality of Life, and Outcomes in Older Patients With Head and Neck Cancers and Lung Cancers Receiving Radiation Therapy. Int J Radiat Oncol Biol Phys (2017) 98(4):850–7. doi: 10.1016/j.ijrobp.2016.11.048

  • 215

    de VriesJBrasLSidorenkovGFestenSSteenbakkersRLangendijkJAet al. Association of Deficits Identified by Geriatric Assessment With Deterioration of Health-Related Quality of Life in Patients Treated for Head and Neck Cancer. JAMA Otolaryngol– Head Neck Surg (2021) 147(12):1089–99. doi: 10.1001/jamaoto.2021.2837

Summary

Keywords

radiation therapy, head neck cancer, surgery, chemotherapy, quality of life, psychosocial distress, sleep, unmet need

Citation

McDowell L, Rischin D, Gough K and Henson C (2022) Health-Related Quality of Life, Psychosocial Distress and Unmet Needs in Older Patients With Head and Neck Cancer. Front. Oncol. 12:834068. doi: 10.3389/fonc.2022.834068

Received

12 December 2021

Accepted

24 January 2022

Published

15 February 2022

Volume

12 - 2022

Edited by

Jan Baptist Vermorken, University of Antwerp, Belgium

Reviewed by

Marshall Posner, Icahn School of Medicine at Mount Sinai, United States; Paul Swiecicki, University of Michigan, United States

Updates

Copyright

*Correspondence: Lachlan McDowell,

This article was submitted to Head and Neck Cancer, a section of the journal Frontiers in Oncology

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics